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Summary 
Transmembrane transporters mediate energy dependent or independent translocation of drugs, 
potentially toxic compounds, and of various endogenous substrates such as bile acids and 
bilirubin across membranes. In this thesis the focus is on two classes of transporters, the ATP-
binding cassette (ABC) transporters, which mediate ATP dependent transport and the solute 
carriers (SLC) which use electrochemical gradients for their transport. The transporters are 
expressed on membranes of cells of excretory organs (e.g. kidney, liver) and protective barriers 
(e.g. intestine, blood brain barrier) and influence therefore the absorption, distribution and 
elimination of compounds. They may reduce the intracellular concentration of drugs.  
Transport activity of transmembrane transporters in the intestine depends on the expression 
level and distribution along the intestine. Transport activity of transporters might be influenced by 
other factors such as genetic variations, which may present with a dysfunctional phenotype (e.g. 
single nucleotide polymorphisms; SNPs), or certain disease states, which might adaptively 
regulate transporter expression on the transcriptional and posttranscriptional level. 
 
The first aim of this thesis was a systematic site-specific analysis of the expression of several 
ABC transporters and solute carriers along the intestinal tract. Following that, regulation of 
hepatobiliary transporters in the human intestine during obstructive cholestasis was evaluated. 
Studies were performed in close collaboration with the Department of Gastroenterology 
(University Hospital of Basel). 
 
As described in Chapter 2, transporter mRNA expression was analyzed by real time PCR 
(Taqman), a method that was previously developed in our laboratory to quantify the expression 
of transporters using standard curves. Protein expression was assessed by 
immunohistochemistry, bile acids plasma concentrations were measured by capillary gas 
chromatography (U. Beuers, Munich). 
 
The results presented in this thesis include systematic site specific analysis of quantitative 
expression of the human multidrug resistance transporters, such MDR1 (ABCB1), breast cancer 
resistance transporter (BCRP; ABCG2) and multidrug resistance associated transporters 
(MRP1-5; ABCC1-5) as well as the apical sodium dependent bile acid transporter ASBT 
(SLC10A2) along the the intestinal tract. These data are shown in Chapter 3. As the mRNA 
expression levels of the investigated transporters change along the intestinal tract, these 
findings might be of interest to develop target strategies for orally administered drugs. 
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Also, this systematic site specific analysis of MDR transporters serves as a preparation for a  
prospective clinical study in patients with Inflammatory Bowel Disease (IBD), which will 
investigate MDR transporter gene expression in intestinal biopsies (intestinal epithelial cells, 
intestinal macrophages) in newly diagnosed IBD patients compared to treatment refractory IBD 
patients, patients in remission and disease free controls. This study design will help to evaluate, 
if MDR transporters vary due to interindividual differences, inflammatory processes and/or 
pharmacological treatment and might serve as an explanation for patients with IBD not 
responding to drug treatment. 
 
Intestinal macrophages play a central role in the orchestration of innate immune response 
reactions in the gut. As anti-inflammatory as well as immunosuppresive drugs such as 
glucocorticoids, methotrexate, cyclosporine, 6-mercaptopurine and sulfasalazine, which all of 
them are used in the treatment of IBD patients, are substrates of MDR transporters,  a method 
for isolation of CD14+ peripheral blood cells (monocytes), their ex vivo cultivation and 
differentiation into macrophages was established. In Chapter 4, first results demonstrate the 
influence of the differentiation process of monocytes into monocyte derived macrophages 
(MDM) and the stimulation of MDM with bacterial products (LPS) on MDR transporter 
expression. At present, the effect of budesonide, methotrexate, 6-mercaptopurine and 
sulfasalazine on the transporter expression in ex vivo cultivated human MDM is evaluated.  
 
Adaptive regulation of hepatobiliary transport systems during obstructive cholestasis with a 
disrupted enterohepatic circulation has been demonstrated in the intestine only for rodents 
before. The results presented in Chapter 3 showed, that ASBT, which contributes substantially 
to the enterohepatic circulation of bile acids by their reabsorption from the intestine, is 
adaptivelly regulated in the human duodenum during obstructive cholestasis. Our findings are of 
clinical importance as we have shown for the first time that ASBT is expressed in the human 
duodenum. These results may indicate species specific differences to rodents, and that changes 
in the ASBT gene expression can be measured in the duodenum during obstructive cholestasis. 
Adaptive regulation of ASBT in the intestine has clinical implications for the bile acid 
homeostasis and also for the lipid metabolism. 
BCRP mediates energy dependent efflux of drugs and potentially toxic compounds, and of 
various endogenous substrates such as bile acids. Here, expression of human BCRP mRNA 
was shown to be highest in the duodenum with a continuos decrease along the intestinal tract 
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down to the rectum. BCRP mRNA and protein expression in the duodenum was found to be 
decreased during obstructive cholestasis when compared to control subjects and BCRP 
expression increased after reconstitution of bile flow. In consequence, reduced intestinal BCRP 
expression during obstructive cholestasis might influence the accumulation of bile acids, food-
derived carcinogens and the pharmacokinetics of various drugs that are transported by BCRP. 
  
In an isolated project with the background of observed therapy resistance to antibiotics in the 
treatment of patients with chronic prostatitis, MDR expression in prostatic tissue in regard to 
inflammation was evaluated in 50 patients that underwent transurethral resection of prostate. In 
this study group, neither inflammation nor localization of inflammation in prostate tissue (acinar 
versus interstitial) influenced MDR transporter expression. 
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Aims of the thesis 
Reabsorption of bile salts from the intestinal lumen is a critical step for bile salt homeostasis in 
the body. Several transporters are involved in this process and mediate energy dependent or 
independent efflux of drugs, potentially toxic compounds, and of various endogenous substrates 
such as bile acids and bilirubin. The aim of the present thesis was to examine the regulation of 
hepatobiliary transport systems in the human gut during obstructive cholestasis with a disrupted 
enterohepatic circulation. A dysregulation of these transport systems in the gut might be of 
clinical relevance for drug treatment regimens during obstructive cholestasis.  
The following questions have been addressed: 
 
- systematic site-specific analysis of several ABC transporters and solute carriers 
expression along the intestinal tract 
- regulation of hepatobiliary transporters in the human intestine on the transcriptional and 
posttranscriptional level during obstructive cholestasis 
 
Beside the focus on regulation of hepatobiliary transport systems in the human intestine an 
important research topic of our lab is the investigation of molecular mechanisms for insufficient 
or failed therapy for patients with inflammatory bowel disease (IBD). 
As macrophages play an important role in host defense, particularly in the inflammatory process 
of acute and chronic disease, a project was started to investigate the influence of IBD drugs and 
cytokines on the regulation of MDR transporter gene expression in peripheral blood monocytes 
and macrophages. The following goals have been set: 
 
-  Establishment of a method for isolation of CD14+ peripheral blood cells (monocytes), ex 
vivo cultivation and differentiation into macrophages 
-  Influence of differentiation into macrophages and stimulation of bacterial products (LPS) 
on MDR transporter expression 
 
In an isolated project the expression of multidrug resistance transporters was studied in prostatic 
tissue of patients diagnosed with benign prostatic hyperplasia (BPH) undergoing transurethral 
resection of the prostate. The following question was addressed: 
 
- Influence of inflammation on MDR transporter expression in human prostatic tissue 
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1. Introduction 
1.1 Physiology of bile salt transporters  
Bile formation is an osmotic secretory process that is driven by the active concentration of bile 
salts (major organic solutes in bile) and other biliary constituents in the bile canaliculi. Bile salts 
are concentrated up to 1000 fold in bile using an active transport by hepatocytes against a 
concentration gradient when secreted into bile ductuli. As it passes along the bile ductules and 
ducts bile is modified by secretory and absorptive processes and is further concentrated up to 
10-fold in the gallbladder before reaching the intestine. In the small intestine bile salts emulsify 
dietary fats and lipid-soluble vitamins. They regulate pancreatic secretion and the release of 
gastrointestinal peptides (Koop et al., 1996). In addition, bile is an important route of elimination 
for environmental toxins, carcinogens, drugs and their metabolites (xenobiotics) and serves also 
as the major route of excretion for endogenous compounds and metabolic products such as 
cholesterol, bilirubin and hormones (Trauner and Boyer, 2003). 
 
 
 
 
Figure: Trauner M et al., J Clin Gastroenterol 2005;39: S111-24 
Figure represents normal bile secretion. Many biliary compounds (eg bile salts, bilirubin, cholesterol) 
secreted into bile undergo an extensive enterohepatic circulation, ie, are reabsorbed in the (small) 
intestine, taken up again by the liver and secreted into bile. Some compounds repeat this cycle for several 
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times before becoming eliminated by the feces. Additional “cycles” include a cholehepatic cycle between 
bile duct epithelial cells (cholangiocytes) and hepatocytes, and a nephrohepatic cycle between kidney 
cells (proximal renal tubules) and liver hepatocytes, the latter preventing the loss of glomerularely filtered 
bile salts into urine. 
 
Bile salts undergo extensive enterohepatic circulation. After reabsorbtion in the proximal small 
intestine by sodium independent absorption and in the distal ileum by active sodium-dependent 
absorption, bile salts return to the liver via the portal circulation. This efficient enterohepatic 
circulation ensures that from the total bile salt pool of adult humans (3-4 g), which circulates 6-
10 times per 24 hours through the enterohepatic pathway only 0.5 g bile salts are lost per 24 
hours through fecal excretion. The loss is compensated by de novo synthesis from cholesterol 
(Meier and Stieger, 2002). 
Hepatic uptake, biliary excretion and intestinal reabsorption are mediated by specific transport 
proteins. More than 80% of conjugated bile salts, which circulate in plasma tightly bound to 
albumin and lipoproteins (Wolkoff and Cohen, 2003) undergo single-pass extraction by the liver. 
Hepatic uptake of bile salts on the basolateral membrane in humans is mediated predominantly 
by the Na+-taurocholate cotransporting protein (NTCP, SLC10A1) for taurine and glycine 
conjugated bile salts (Hagenbuch and Meier, 1994; Meier et al., 1997) and the Na+ independent 
organic anion-transporting polypeptide (OATP-C) (Kullak-Ublick et al., 2001). The canalicular 
secretion of conjugated bile salts on the apical membrane of the hepatocyte represents the rate 
limiting step in the overall bile salt transport from blood into bile. The secretion into bile canaliculi 
is performed by the bile salt export pump (BSEP), which is a member of the ATP-binding 
cassette (ABC) transporter gene superfamily. Bsep knockout mice exhibit liver steatosis with 
mild cholestasis. However, they demonstrate residual bile salt secretion of about 30% compared 
with wild type mice (Wang et al., 2001b). Mutations in the human BSEP-gene are associated 
with progressive familial intrahepatic cholestasis (PFIC2) (Strautnieks et al., 1998). These 
patients secrete less than 1% of biliary salts compared with normal infants (Jansen et al., 1999). 
The exact contribution of multidrug resistance associated protein 2 (MRP2), which is localized 
on the canalicular membrane, to canalicular transport of bile salts is currently under investigation 
(Keppler and Konig, 2000). However, mutations in MRP2 have been reported to underly Dubin-
Johnson syndrome that is characterized by a defective excretion of conjugated anions into the 
bile (chronic conjugated hyperbilirubinemia) (Hashimoto et al., 2002). MRP2 is deficient in rats 
with an inborn error in the biliary secretion of organic anions, including conjugated bilirubin 
(Buchler et al., 1996; Paulusma et al., 1996).  
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BCRP (ABCG2) another ABC transporter is localized on the canalicular membrane of the 
hepatocyte and physiologic substrates include estrone-3-sulfate, dehydroepiandrosterone 
sulphate and sulfasalazine (Suzuki et al., 2003). Its role for the hepatobiliary transport has not 
been completely elucidated, yet. 
 
1.2 Intestinal transporters for reabsorption of bile salts 
 
A critical step for the bile salt homeostasis is the reabsorption of bile salts from the intestine in 
which different transporters might be involved. In the brush border membrane of jejunal 
enterocytes in rats the organic anion transporting protein (Oatp3) is expressed (Walters et al., 
2000). This sodium independent bile salt transporter transports a large variety of organic anions 
and bile salts (Kullak-Ublick et al., 2000). However, whether functional expression of bile salt -
transporting OATPs also occurs in the brush border membrane of the human intestine remains 
to be elucidated. Reabsorption of bile salts mainly occurs in the distal ileum where the apical 
sodium-dependent bile salt transporter (ASBT/SLC10A2) is expressed. Human ASBT transports 
conjugated and unconjugated bile salts with a higher affinity for CDCA and DCA than for 
taurocholate (Craddock et al., 1998). Patients with mutations in the ASBT gene can suffer from 
congenital diarrhea and steatorrhea, concomitant with an interrupted enterohepatic circulation of 
bile salts (Oelkers et al., 1997). Induction of Asbt mRNA levels, transporter protein and transport 
activity by cholic acid feeding in rats was observed (Stravitz et al., 1997).  
After uptake into the enterocyte, bile salts are shuttled to the basolateral membrane for efflux 
into the portal circulation. Transcellular transport is probably mediated by the ileal bile acid-
binding protein (I-BABP) that is cytoplasmatically attached to ASBT (Gong et al., 1994). 
Multidrug resistance associated protein 3 (MRP3) is expressed in increasing levels from the 
jejunum to the large intestine (Cherrington et al., 2002) and is localized on the basolateral 
membrane of polarized cells (Konig et al., 1999; Kool et al., 1999). MRP3 transports substrates 
such as conjugated bile salts and bilirubin glucuronide (Hirohashi et al., 2000; Keppler et al., 
2000; Zelcer et al., 2003) and is a potential candidate for bile salt efflux from enterocytes into 
portal blood. In Caco2-cells bile salts increased the expression of human MRP3 (Inokuchi et al., 
2001) and in an in-vitro study with LLC-PK1 cells transfected with rat MRP3 the involvement of 
MRP3 in bile salt transport could be demonstrated (Hirohashi et al., 2000). A recent publication 
showed that the organic solute transporters (Ost)-α and Ost-β are localized in the intestine 
predominantly on the basolateral membrane of ileocytes. These transporters form a heterodimer 
and mediate apical efflux of taurocholate in transfected canine kidney cells and seems to be 
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responsible for the transport of bile salts across the basolateral membrane of enterocytes into 
portal blood (Dawson et al., 2005). 
 
 
 
Figure: Trauner M et al., J Clin Gastroenterol 2005;39: S111-24 
Hepatobiliary transport systems in liver and extrahepatic tissues in humans. Bile salts (BS-) are taken up 
by hepatocytes via the basolateral Na+ /taurocholate cotransporter (NTCP) and organic anion transporting 
proteins (OATPs). Monovalent BS- are excreted via the canalicular bile salt export pump (BSEP) while 
divalent BS- together with anionic conjugates (OA-) are excreted via the canalicular conjugate export 
pump (MRP2). The phospholipids export pump (Mdr2/MDR3) facilitates excretion of phosphatidylcholine 
(PC), which forms mixed micells in bile together with BS- and cholesterol. Cationic drugs (OC+) are 
excreted by the multidrug resistance export pump (Mdr1). Other canalicular export pumps include the two-
half transporter Abcg5/g8 for cholesterol and the breast cancer resistance protein (Bcrp) for OA- (not 
shown). Basolateral isoforms of the multidrug resistance-associated protein (MRP3 and MRP4) provide an 
alternative route for the elimination of BS- and nonbile salt OA- from hepatocytes into systemic circulation. 
BS- are reabsorbed in the terminal ileum via ileal Na+  -dependent bile salt transporter (ASBT) and effluxed 
by the recently identified heterodimeric organic solute transporter Ost α/β. Similar mechanisms exist in 
proximal renal tubules and cholangiocytes where an additional, truncated isoform (t-ASBT) or MRP3 may 
be involved in BS- efflux from cholangiocytes. In addition to ASBT and MRPs, proximal renal tubules 
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express Oatp1 (not shown). MRP2 is also present in the apical membrane of enterocytes and proximal 
renal tubules, while MDR1 is also found in intestine and bile ducts. 
 
1.3 Transcriptional regulation of transporters involved in bile salt transport 
The functional expression of membrane transport proteins can be regulated at several levels, 
including gene transcription and posttranscriptional activity. Although the mechanism that control 
gene transcription of membrane transporters are still incompletely understood, bile salt uptake 
and efflux systems might be regulated by the following nuclear hormone receptors as well as 
other transcription factors. Bile salts, sterols and fatty acids are natural ligands of nuclear 
hormone receptors expressed in liver and intestine. The requirement for a regulatory network for 
maintaining a bile salt homeostasis in the human body is evident from the fact that the 
intracellular accumulation of bile salts leads to cholestasis, hepatocyte apoptosis and 
parenchymal damage (Faubion et al., 1999). 
 
1.3.1 Farnesoid X receptor (FXR) and retinoid X receptor (RXR) 
FXR, which is highly expressed in the liver and intestine, but also in the adrenal gland and 
kidney, plays a dominant role in the regulation of bile acid synthesis and bile salt transport. FXR 
belongs to the NR1 family of nuclear receptors. Studies where transfection of expression 
plasmids containing murine and human FXR into monkey kidney CV-1 or human hepatoma 
HepG2 cells was performed, demonstrated that CDCA is the most effective activator of FXR 
(Makishima et al., 1999). The other bile acids, such as lithocholic acid and deoxycholic acid 
were found to be less effective. FXR together with its heterodimeric partner RXR acts as a 
transcription factor for several bile salt transporters, such as the hepatic bile salt export pump 
Bsep (Ananthanarayanan et al., 2001), the ileal bile acid binding protein I-Babp (Grober et al., 
1999) and MRP2 (Kast et al., 2002). Recently, it was shown that human OSTα/OSTβ expression  
is induced by bile acids through ligand-dependent transactivation of both OST genes by FXR 
(Landrier et al., 2005). 
In addition, the expression of short heterodimeric protein (SHP-1), which acts as a 
transcriptional repressor, is itself regulated by FXR and can downregulate the expression of 
several genes including Ntcp (Denson et al., 2001) and cholesterol 7α- hydroxylase CYP7A1, 
the rate limiting enzyme in bile salt synthesis from cholesterol. Repression of the rat Ntcp gene 
occurred via SHP-mediated inhibition of retinoid activation of the RARα:RXRα element. Bile acid 
feeding of mice markedly upregulated the expression of SHP-1 mRNA while reducing the 
expression of CYP7a1 (Lu et al., 2000). Activation of bile acid synthesis is suppressed by the 
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nuclear receptor SHP-1 by binding and repressing the transcriptional activity of the nuclear 
receptor liver receptor homolog (LRH-1) (Goodwin et al., 2000) and hepatocyte nuclear factor 
(HNF) 4α (Lee et al., 2000b), which are essential activators of the bile acid synthetic enzymes 
CYP7A1 and CYP8B1. However, partial maintenance of negative feedback regulation of bile salt 
synthesis in SHP null mice indicates the existence of SHP independent pathways (Kerr et al., 
2002). 
 
1.3.2 Pregnane X receptor (PXR) and Constitutive androstane receptor (CAR) 
The pregnane X receptor (PXR) also known as steroid X receptor (SXR) in humans and the 
constitutive androstane receptor (CAR) play besides FXR an important role in the regulation of 
bile salt transporters. Furthermore they act as activators of detoxifying proteins (e.g. cytochrome 
P450 enzymes or transporters) and they enhance metabolism of potentially toxic xenobiotics 
and other compounds. They promote the metabolism and excretion of lipophilic substances from 
the body. Ligands of PXR include rifampicin, RU486, St. Johns wort extract, clotrimazol, 
steroids, statins, phenobarbital, bile salts and bile acid precursors and for CAR xenobiotics and 
phenobarbital, respectively (Kullak-Ublick et al., 2004). After interaction between the receptor 
and a specific ligand (Kliewer et al., 1999), ligand binding induces a conformational change 
within the receptor that facilitates binding of co-activator proteins (e.g. RXR). This heterodimer 
regulates the transcription of the target gene by binding to specific DNA response elements 
(Renaud and Moras, 2000). Concretely, PXR binds with RXR as a heterodimer to a “xenobiotic 
response element” in the promoter of the human CYP3A4 gene (Blumberg et al., 1998).  
Targeted disruption of the mouse PXR gene abolishes the ability of xenobiotics to induce 
CYP3A. The importance of PXR for the regulation of CYP3A was demonstrated by an abolished 
protective effect of pregnolone-16-α-carbonitrile (a potent inducer of CYP3A) in PXR null mice 
after feeding with lithocholic acid which produces severe hepatic necrosis in mice (Staudinger et 
al., 2001; Xie et al., 2001). 
Interestingly, rifampicin which is another potent ligand for SXR and inducer of CYP3A has been 
shown to be effective in the treatment of symptoms of pruritus in cholestatic disease (Cancado 
et al., 1998). It has been speculated that rifampicin may stimulate 6-α-hydroxylation of bile acids, 
leading to glucuronidation by UDP-glucuronosyl transferases and excretion bile salts by 
alternative pathways in the urine (Bremmelgaard and Sjovall, 1979; Wietholtz et al., 1996; Araya 
and Wikvall, 1999).  
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PXR is mainly expressed in the liver and intestine and other target genes that are activated by 
these receptors include Pgp, MRP2, MRP3, and OATP2 (Kast et al., 2002; Staudinger et al., 
2003; Wang and LeCluyse, 2003). 
 
CAR which is constitutively and highly expressed in the liver binds DNA as heterodimer with 
RXRα. Upon stimulation by a ligand CAR translocates from the cytoplasma to the nucleus. CAR 
stimulates the expression of MRP2 (Kast et al., 2002), MRP3 (Cherrington et al., 2002) and 
CYP2B1 (Xiong et al., 2002).  
 
Although PXR and CAR are involved in signalling pathways that protect the body from 
xenobiotics, their activation by drugs represents the molecular basis for an important class of 
drug-drug interactions. Assays that detect PXR activation during drug development are used to 
predict and prevent these drug-drug interactions (Moore and Kliewer, 2000). Most cases of such 
interactions are related to elevated P-gp expression that lead to a decrease of the plasma level 
of concomitantly administered P-gp substrates. Whereas paclitaxel activation of PXR was 
leading to enhanced P-gp mediated drug clearance, docetaxel did not activate PXR. In contrast, 
ET-743, another potent antineoplastic agent, suppressed MDR1 transcription by acting as an 
inhibitor of PXR (Synold et al., 2001). These examples demonstrate how the molecular activities 
of nuclear receptors can control drug clearance. 
 
1.3.3 Peroxisome proliferator activated receptor α (PPAR α) 
The nuclear receptor PPARα, a ligand activated transcription factor that regulates the 
expression of a number of genes involved in peroxisomal and mitochondrial β-oxidation of fatty 
acids, activates the apical sodium-dependent bile salt transporter (ASBT/SLC10A2) (Jung et al., 
2002) and the hepatocyte canalicular phospholipids flippase Mdr2/MDR3 (ABCB4) (Kok et al., 
2003). The ligands include fatty acids, fibrates, eicosanoids and NSAIDS (Desvergne and Wahli, 
1999). Upon activation, PPARα binds as a heterodimer with the retinoid X receptor (RXR) to a 
peroxisome proliferator-response element (PPRE) located in the promoter region of target 
genes.  
The observation that patients with type IV hypertriglyceridemia exhibited decreased intestinal 
bile salt absorption and reduced ileal expression of ASBT mRNA postulated a possible link 
between intestinal bile salt absorption via ASBT and hepatic fatty acid catabolism (Duane et al., 
2000). PPARα was shown to play a critical role in the adaptive response to fasting in mice 
(Kroetz et al., 1998; Kersten et al., 1999; Leone et al., 1999) and PPARα also influences bile 
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acid composition by induction of the sterol 12α-hydroxylase, which acts at a branch-point in the 
bile acid synthetic pathway by catalizing the conversion of 7α-hydroxy-4-cholesten-3-one to 
7α,12α-dihydroxy-4-cholesten-3-one. This reaction determines the ratio of cholic acid to 
chenodeoxycholic acid. (Hunt et al., 2000) In Hepa 1c1c7 cells, which were transiently 
transfected with an expression plasmid for PPARα and RXRα and a luciferase reporter 
construct containing copies of the rat PPRE, an inhibition of PPARα reporter gene expression 
was shown with increasing concentrations of chenodeoxycholic acid (CDCA) in the presence or 
absence of Wy-14,643 (=PPARα ligand) (Sinal et al., 2001). It was concluded that during certain 
pathophysiological states, where intracellular bile acid concentrations might be elevated, effects 
on PPARα-dependent target gene regulation are possible (Sinal et al., 2001). In addition, 
PPARα was shown to transactivate the human ASBT gene (Jung et al., 2002). Incubation of 
human hepatoma HepG2 cells with CDCA resulted in a significant induction of PPARα mRNA 
levels and hPPARα gene expression was upregulated by taurocholic acid in human primary 
hepatocytes (Pineda Torra et al., 2003). 
In addition to these ligand-activated nuclear receptors, other factors such as the hepatocate 
nuclear factor (HNF) family of liver enriched transcription factors including HNF1α, HNF3β and 
CCAAT/enhancer binding protein (C/EBP), as well as sterol responsive element binding protein 
(SREBP) and nuclear factor kappa B (NF-κB) also appear to play an important role in the 
regulation of bile salt transporters (Trauner and Boyer, 2003). 
Another interesting inductor of intestinal Na+ dependent bile salt transport seems to be the 
glucocorticoid receptor (GR), a nuclear steroid receptor. The human ASBT gene has been 
shown to be transactivated by the GR and its ligands dexamethasone and budesonide (Jung et 
al., 2004).  
 
1.3.4 Cholestasis 
Cholestasis is an impairment of bile secretion which may result either from a functional defect in 
bile formation at the level of hepatocytes (hepatocellular cholestasis: autoimmune, metabolic, 
infectious, genetic disorders) or from an impairment in bile secretion (transmembrane transport 
systems in hepatocytes and cholangiocytes) or from disturbed structural and/or functional 
integrity of the bile secretory pathway (Trauner et al., 1998). Under cholestatic conditions with 
impaired bile secretion, the enterohepatic circulation is disrupted. In animal models, rats with 
common bile duct ligation (CBDL) showed an impaired expression and function of the hepatic 
uptake (Ntcp/Slc10a1, Oatps/SLC21a) and excretory systems (Bsep/Abcb11, Mrp2/Abcc2) 
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(Trauner et al., 2005). In obstructive cholestasis, an increased cholehepatic shunting, as shown 
by increased expression of cholangiocellular Asbt, removes stagnant bile salts from the 
obstructed ducts returning them to the systemic circulation. The impaired expression and 
function of hepatic uptake systems, reduced expression of Asbt in the kidney, a change 
associated with a diminished capacity to reabsorb bile salts from the glomerular filtrate as well 
as an up-regulation of Mrp2 protein expression on the apical membrane of the rat renal proximal 
tubule (Lee et al., 2001) facilitates the excretion of bile salts by this alternative excretory route. 
MRP2 is associated with an increased ability to excrete divalent organic anions such as bile salt 
sulfates and glucuronides (bilirubin) that accumulate during cholestasis and would therefore 
facilitate extrahepatic pathways for bile salt and bilirubin excretion during cholestasis. In the 
intestine of bile duct-ligated rats down-regulation of ASBT expression in the terminal ileum was 
shown. The intestinal absorption rate of taurocholate was lower and the absorption rate was 
inversely correlated to serum bile salt concentrations when compared to sham operated rats 
(Sauer et al., 2000).  
Apart from species differences in bile acid composition and transporter gene regulation, a major 
obstacle for a direct extrapolation of rodent data to human data is the different duration of 
cholestasis in animal models (day to weeks) versus human cholestatic disorders (weeks to 
months/years). Findings from animal experimental models can not be unequivocally applied to 
human cholestatic diseases. Therefore, in this thesis the effect of an obstructed bile secretory 
pathway on the intestinal expression of bile salt transporters and on regulatory proteins was 
investigated in human subjects. 
 
1.4 ABC transporters 
The ATP-binding cassette (ABC) transporters represent a large and diverse superfamily of 
transmembrane proteins which bind ATP and use the energy to drive the transport of various 
molecules across cell membranes. A complete ABC transporter consist of transmembrane 
domains which anchor the transporter in the lipid bilayer and two ATP-binding domains, also 
known as nucleotide binding folds (NBFs). Proteins are classified based on the sequence and 
organization of their nucleotide binding folds (NBFs). The transporters share extensive 
sequence homology and domain organisation including the characteristic ATP-binding cassette. 
They are classified into seven subfamilies (ABCA to ABCG). Their main function is the 
unidirectional, energy dependent translocation of compounds from the cytoplasm to the outside 
of the cell or into an intracellular compartment (endoplasmic reticulum (ER), mitochondria, 
peroxisome) against a concentration gradient.  
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The first member discovered in 1976 (Juliano and Ling, 1976) was P-glycoprotein (MDR1; 
ABCC1). This protein appeared to be overexpressed in tumour cells with a multidrug resistance 
phenotype where it conferred resistance to many unrelated cytotoxic drugs. Later the existence 
of the multi-drug resistance associated proteins (MRPs; ABCC) was revealed. Some of these 
transporters are relevant for drug transport, as well as the recently discovered ABC transporter 
breast cancer resistance protein (BCRP; ABCG2).  
In this thesis MDR1 (ABCB1), MRP1-5 (ABCC1-5) as well as BCRP (ABCG2) were of particular 
interest, since these proteins can have a major impact on drug absorption and disposition, 
extrusion of toxic compounds to the outside of the cell and are involved in the transport of 
endogenous substrates, among others bile acids, bilirubin or cholesterol (Gottesman et al., 
2002).  
 
1.4.1 MDR1 (ABCB1) 
MDR1 is the best characterized ABC transporter. P-glycoprotein (P-gp), the gene product of 
MDR1 has a molecular weight of 170 kDa and consists of 12 transmembrane domains and two 
nucleotide-binding sites. P-gp is expressed on the apical membrane of normal tissues such as 
intestine, kidney, liver, adrenal gland and blood-brain barrier. By limiting absorption and 
enhancing the excretion of toxic compounds/metabolites P-gp is assumed to function as 
gatekeeper against toxic xenobiotics in the gut or in the blood-brain barrier (Tanigawara, 2000). 
P-gp is a transporter with extreme wide substrate specificity and many unrelated substances 
were identified as P-gp substrates. However, a tendency towards organic compounds with 
cationic or amphiphatic nature could be determined (Schinkel and Jonker, 2003). The high 
expression in solid tumours indicated the pivotal role of Pgp in clinical resistance to 
chemotherapy. Individual differences in expression and/or activity of MDR1 (P-gp) were shown 
to lead to changes in drug bioavailability (Lown et al., 1997).  
Moreover, genetic variants (single nucleotide polymorphisms, SNPs) can alter P-gp expression 
and function, as well as may also predispose to certain diseases. To date 28 SNPs have been 
identified in the MDR1 gene, whereas 11 SNPs resulted in an amino acid exchange (Schwab et 
al., 2003). The most important is the C3435T polymorphism, for which it was found that about 
25% of Caucasian subjects were homozygous for this polymorphism (Cascorbi et al., 2001). 
This polymorphism does not influence the amino acid sequence but is associated with an altered 
P-gp expression and function. On average, the TT homozygotes have a lower level of intestinal 
Pgp resulting in an increase of digoxin plasma levels, compared to the CC genotype group 
(Hoffmeyer et al., 2000). C3435T is also reported to be a risk factor for certain class of diseases 
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including inflammatory bowel disease, Parkinson’s disease and renal epithelial tumour 
(Siegsmund et al., 2002; Schwab et al., 2003; Sakaeda et al., 2004). 
Interactions are likely to occur in multidrug therapy as P-gp transports a wide range of 
structurally diverse drugs and a large number of drugs potentially influence MDR activity and 
even some drugs alter the expression of MDR1. It has been reported that P-gp inhibitors such 
as verapamil, itraconazole, ritonavir, and talinolol increased the plasma concentrations of the P-
gp substrate digoxin due to inhibition of P-gp mediated efflux (Verschraagen et al., 1999; 
Westphal et al., 2000a; Angirasa and Koch, 2002; Ding et al., 2004). Additionally, P-gp has also 
been shown to be inducible in vitro and in vivo by xenobiotics such as rifampicin (Westphal et 
al., 2000b), Phenobarbital (Lu et al., 2004), dexamethasone (Fardel et al., 1993), and herbal 
extracts from St. John’s wort (Zhou et al., 2004). Interestingly even components of our daily 
nutrition, e.g. grapefruit juice have been shown to influence MDR1 activity (Soldner et al., 1999; 
Wang et al., 2001a). Increased P-gp expression can therefore lead to subtherapeutic 
concentrations of concomitantly administered substrates. 
MDR1 inhibitors are evaluated in clinical trials of chemotherapy to reduce multidrug resistance 
(Kornblau et al., 1997).  
 
 
1.4.2 MRP1-5 (ABCC1-5) 
The family of multi-drug resistance associated proteins (MRPs) is another important group of 
human ABC transporters that are relevant for drug transport. All of them possess the 
characteristic ATP binding cassette motive but they vary in the number of their transmembrane 
domains. So far, this subfamily includes nine members (MRP1-9). In contrast to P-gp, MRPs 
work mainly as transporters of amphiphatic organic anions. Therefore, they are capable to 
extrude drug conjugates, such as glucuronide-, glutathione-, and sulphate-conjugates out of 
cells. 
 
MRP1 (ABCC1) is ubiquitously expressed in the body and is localised on the basolateral 
membrane of epithelial cell layers as well as in the ER and post-Golgi vesicles. Physiological 
important substrates for MRP1 include glutathione S-conjugates such as leukotriene C4, as well 
as glucuronate and sulphate conjugates, e.g. bilirubin glucuronides (Keppler et al., 1998). In 
addition, anionic drugs and drugs like methotrexate or arsenite are also transported by MRP1 
(Bakos et al., 2000). MRP1 drug resistance phenotype overlaps with that of Pgp and is 
associated with resistance to anthracyclines, etoposide and vinca alkaloids. 
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MRP2 (ABCC2) is expressed in the liver, intestine, kidney, placenta and blood- brain barrier. It 
mediates the transport of drugs and conjugated compounds into bile, intestinal lumen and urine, 
respectively and therefore out of the body (Schaub et al., 1997; Kusuhara and Sugiyama, 2002). 
The substrate specificity of MRP2 is similar to that of MRP1, and includes glutathion conjugates, 
billirubin glucuronides, and a number of drugs and their conjugated drug metabolites 
(Jedlitschky et al., 1997; Kawabe et al., 1999). These drugs include temocaprilat, irinotecan, SN-
38, arsenite, cisplatin, methotrexate, vincristine, saquinavir, and ceftriaxone (Kusuhara and 
Sugiyama, 2002; Dietrich et al., 2003). Similar to MDR1, MRP2 seems to be inducible by 
rifampicin treatment (Fromm et al., 2000), which indicates possible interactions in multidrug 
therapy. Influence on the MRP2 protein expression was also shown for tamoxifen (Kauffmann et 
al., 1998). In addition, MDR1 and MRP2 share some substrates as well as inhibitors, which may 
lead to interactions and influence the oral bioavailability of certain drugs. Similarly to MDR 1 
some components of our daily diet, such as the flavonoid epicatechin in tea (Vaidyanathan and 
Walle, 2001), chrysin and its metabolites (Walle et al., 1999) were shown to be substrates of 
MRP2. 
As MRP2 is expressed in the tips of the intestinal villi, which are atrophic in celiac sprue, the 
reduction of MRP2 protein expression might be associated as consequence with impaired 
clearing of MRP2 substrates (Dietrich et al., 2003).  
Polymorphisms, as described for MDR1, have also been shown for MRP2 (Itoda et al., 2002a; 
Itoda et al., 2002b), but neither frequency nor influence on transporter activity or expression 
have yet been defined. In patients with the Dubin-Johnson syndrome MRP2 is completely 
absent in canalicular membranes of hepatocytes and apical membranes of enterocytes due to a 
nonsense mutation in the MRP2 gene resulting in truncation and degradation of the protein. The 
absence of this transporter in the hepatocyte canicular membrane leads to impaired biliary 
secretion of glutathione, glutathione conjugates, and bilirubin glucuronides (Paulusma et al., 
1997). If individual differences in MRP2 gene and protein expression might have influence on 
the prevalence of certain intestinal diseases, such as Crohns disease and celiac sprue is 
currently under inverstigation. 
 
MRP3 (ABCC3), like MRP1, is present on the basolateral membrane of polarized cells, mainly in 
liver, intestine and kidney (Scheffer et al., 2000). Substrates of MRP3 include glucuronate 
conjugates. MRP3 transports a wide range of bile salts and seems to be involved in their 
reabsorption to the portal blood on the basolateral membrane of the intestinal epithelial cells 
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(Hirohashi et al., 2000). MRP3-transfection of cell lines conferred resistance to 
epipodophyllotoxins, vincristine and methotrexate (Kool et al., 1999). Therefore, MRP3 may also 
contribute to a protective function by excreting a range of toxic substances from various 
epithelial cell types. 
 
MRP4 (ABCC4) and MRP5 (ABCC5) are 2 structurally similar members of the MRP family and 
are both capable of transporting therapeutic nucleoside based compounds (Schuetz et al., 1999; 
Lee et al., 2000a; Chen et al., 2001). 
For MRP4, there are no definite data concerning cellular localization or tissue distribution. For 
instance, it has been reported that MRP4 is located on the basolateral membrane of prostate 
cells (Lee et al., 2000a), whereas others showed MRP4 expression on the apical membrane of 
kidney cells (van Aubel et al., 2002). The significance of MRP4 in drug transport is at present 
unclear as well. However, an over-expression of MRP4 severely impaired the antiviral efficacy of 
adefovir, azidothymidine, 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and of other 
nucleoside analogs in PMEA-resistant lymphoblastoid cell line (Schuetz et al., 1999). This 
finding has two potential clinical significances and may affect therapeutic response. First, MRP4 
can decrease the intracellular concentration of the respective antiretroviral drug, which leads to 
impaired suppression of HIV replication. Second MRP4 overexpression in cells lines can protect 
from the cytotoxic effects of antiretroviral drugs.  
MRP4 can be considered to be an organic anion transporter, as is expected for an MRP family 
member. Other substrates include folic acid, bile acids, methotrexate and 6-mercaptopurine 
(Wielinga et al., 2002). A physiological role of MRP4 might be the release of prostaglandins from 
cells (Reid et al., 2003). 
MRP5 (ABCC5) is widely expressed throughout most tissues. Like MRP4, it has an affinity to 
nucleotidebased substrates. A study demonstrated that MRP5 transports the cyclic nucleotides 
cAMP and cGMP (Jedlitschky et al., 2000), but the physiological function of this transporter 
remains to be elucidated. There are no reports at present, which could suggest a role for MRP5 
in drug disposition. Experiments with transfected cells showed enhanced efflux of DNP-SG (2,4-
dinitrophenyl-S-glutathione), adefovir, and the purine analogues 6-mercaptopurine and 
thioguanine (Wijnholds et al., 2000). 
 
1.4.3 ABCG2 (BCRP) 
Human breast cancer resistance protein (BCRP, ABCG2), which belongs to the ABC transporter 
family, was discovered and cloned by Doyle et al. from a doxorubicin-resistant MCF7 breast 
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cancer cell line (MCF7/AdrVp) (Doyle and Ross, 2003). Structurally, BCRP is a half-transporter 
(one nucleotide-binding domain, 6 transmembrane domains) and it seems very likely that it 
functions as a homodimer (Ozvegy et al., 2001). Whether BCRP can also function as a 
heterodimer with other halftransporters of the ABCG class is not known. BCRP is expressed in 
different tissues, among others in the bile canalicular membrane of hepatocytes and in the apical 
membrane of intestinal epithelial cells (Doyle and Ross, 2003). It is a transporter with a wide 
substrate specificity recognizing molecules of either negative or positive charge, organic anions 
and sulphate conjugates. Antitumor agents have been widely examined and BCRP can render 
tumor cells resistant to the anticancer drugs topotecan, mitoxantrone, doxorubicin, and 
daunorubicin (Jonker et al., 2000). Also, BCRP mediates apically directed drug transport, 
appears to reduce drug bioavailability, and protects fetuses against drugs (Jonker et al., 2000). 
Recently, BCRP induction in human T-cells was observed after prolonged exposure to 
sulfasalazine. In the same study enhanced TNFα release and an insufficient inhibition of TNFα 
production by sulfasalazine was demonstrated, suggesting that drug resistance might also be 
induced by anti-inflammatory agents such as sulfasalazine (van der Heijden et al., 2004a; van 
der Heijden et al., 2004b). 
 
1.5 Solute carrier (SLC) 
The SLC (Solute Carrier) family includes ion coupled transporters, facilitated transporters, and 
exchangers. The genes encoding these transporters are divided into 43 gene families (SLC1-43, 
according to the HUGO Gene Nomenclature Committee) and include 298 transporter genes at 
present (Hediger et al., 2004). These SLC membrane proteins use cellular chemical and/or 
electrical gradients to move molecules across cell membranes. Physiologically, they transport 
many endogenous substances such as amino acids, glucose, bicarbonate, bile acids, ascorbic 
acid, urea or fatty acids. However, members of this superfamily can also be involved in drug 
transport and play a role in drug disposition. Many of them are expressed in important organs for 
drug disposition such as kidney, liver, and intestine. Here, the expression and regulation of the 
apical sodium dependent bile salt transporter (ASBT, SLC10A2) was investigated, which 
represents a critical component of the enterohepatic circulation of bile salts.  
 
1.5.1 Na+/ taurocholate cotransporting polypeptide (NTCP; SLC10A1), Apical sodium 
dependent bile salt transporter (ASBT, SLC10A2) 
NTCP and ASBT belong to the same family of solute carriers. By reabsorbing bile salts from the 
blood, bile, glomerular filtrate as well as intestinal lumen they are critical determinants of the 
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enterohepatic circulation of bile salts. Both are cotransporters that mediate sodium-dependent 
bile salt uptake into hepatocytes (NTCP), cholangiocytes, enterocytes and renal proximal tubular 
cells (ASBT), respectively.  
ASBT is a membrane glycoprotein which consists of 348 amino acids and is expressed on the 
apical membrane of enterocytes in the terminal ileum, of proximal renal tubular cells and of 
cholangiocytes. Human ASBT transports conjugated and unconjugated bile salts with a higher 
affinity for CDCA and DCA than for taurocholate (Craddock et al., 1998). Subjects with 
mutations in the ASBT gene suffer from congenital diarrhea and steatorrhea, due to bile salt 
malabsorption (Oelkers et al., 1997) and pharmacological inhibition of the transport activity leads 
to interruption of enterohepatic circulation of bile salts with changes in the cholesterol and bile 
acid homeostasis (Lewis et al., 1995; Huff et al., 2002; West et al., 2002; Bhat et al., 2003; 
Telford et al., 2003). Adaptive induction of ASBT mRNA expression, transporter protein and 
transport activity was observed in cholic acid fed rats (Stravitz et al., 1997), whereas decreased 
ASBT expression was found in the ileum of bile duct ligated rats (Sauer et al., 2000). 
The transcriptional regulation of bile salt transporters, as already described in Chapter 3 is very 
complex, and the intracellular factors that influence ASBT gene expression remain largely 
unknown. One such potential factor might be the nuclear receptor PPARα, a ligand activated 
transcription factor that regulates the expression of a number of genes involved in peroxisomal 
and mitochondrial β-oxidation of fatty acids. PPARα binds as a heterodimer with the retinoid X 
receptor (RXR) to a peroxisome proliferator-response element (PPRE) located in the promoter 
region of target genes. PPARα was shown to play a critical role in the adaptive response to 
fasting in mice (Kroetz et al., 1998; Kersten et al., 1999; Leone et al., 1999) and PPARα also 
influences bile acid composition by induction of the sterol 12α-hydroxylase, which determines 
the ratio of cholic acid to chenodeoxycholic acid (Hunt et al., 2000). Recently, PPARα was 
shown to transactivate the human ASBT gene (Jung et al., 2002). In addition, hPPARα gene 
expression was upregulated by taurocholic acid in human primary hepatocytes (Pineda Torra et 
al., 2003).  
NTCP is a membrane glycoprotein which consists of 349 amino acids and shares about 35% 
amino acid identity with the human ASBT. The human NTCP is expressed on the basolateral 
membrane (sinusoidal membrane) of human hepatocytes and promotes by its high affinity for 
conjugated bile salts the extraction of bile salts from portal blood into the hepatocytes. NTCP 
was not investigated in this thesis. Additional informations are provided in a review by 
Hagenbuch et al. (Hagenbuch and Dawson, 2004). 
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2. Material and Methods 
 
2.1 Absolute quantification of transporter mRNA expression 
(quantitative real-time RT-PCR) 
 
2.1.1 Introduction 
Reverse transcription polymerase chain reaction (RT-PCR) is the most common method for 
analysing mRNA expression patterns and comparing mRNA levels in different samples. In this 
thesis, real time RT-PCR (TaqMan®) was used to measure gene expression in human tissue or 
cell lines. With this method the specific gene products generated during each cycle of the PCR 
can be reliably measured and are directly proportionate to the amount of template prior to the 
start of the PCR. Prior to PCR amplification the isolated cellular mRNA was reverse transcribed 
into cDNA which subsequently was quantified with TaqMan® analysis using the standard curve 
method. By using external standards that comprise known amounts of specific cDNA fragments 
of the gene of interest, the unknown amount of cDNA in the analysed samples could be 
expressed as absolute transcript numbers of the corresponding gene. 
 
2.1.2 Real-time PCR (TaqMan® assay) 
The 5`nuclease assay or TaqMan® assay is a highly sensitive method to determine mRNA 
levels quantitatively. This method uses a target specific oligonucleotide, the TaqMan probe, 
which anneals between the forward and reverse primer sites. The probe carries a reporter dye 
on the 5`end (6-carboxy-fluorescein) and a quencher dye on the 3` end (6-carboxy-tetramethyl-
rhodamine). As long as the probe is intact the fluorescence of the reporter dye is suppressed by 
the quencher dye. However, during the PCR the DNA polymerase (Taq polymerase) cleaves the 
probe due to its 5`-3` exonuclease activity. Now, a fluorescent signal is generated because the 
reporter dye is separated from the quencher dye. Consequently, there is an increase of 
fluorescence after each PCR cycle. With the ability to measure the PCR products as they are 
accumulating, in "real time," it is possible to measure the amount of PCR product at a point in 
which the reaction is still in the exponential range. It is only during this exponential phase of the 
PCR reaction that it is possible to extrapolate back to determine the starting amount of template. 
During the exponential phase in real-time PCR experiments, a fluorescence signal threshold is 
determined at which point all samples can be compared. Therefore, the number of PCR cycles 
required to generate enough fluorescent signal to reach this threshold is defined as the cycle 
threshold, or Ct. These Ct values are directly proportionate to the amount of starting template 
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and are the basis for calculating mRNA expression levels. The baseline is defined as the PCR 
cycles in which a signal is accumulating but is beneath the limits of detection of the instrument.  
For each study, TaqMan experiments were carried out either on a Gene Amp 5700 Sequence 
Detector using 96 well plates with total reaction volumes of 25 µL, or on a 7900HT Sequence 
Detection System using 384 well plates with total reaction volumes of 10 µL (all Applied 
Biosystems, Rotkreuz, Switzerland). PCR conditions were throughout 10 min 95°C followed by 
40 cycles of 15 s 95°C and 1 min 60°C. TaqMan Unive rsal PCR Mastermix (Applied 
Biosystems) was used. Each reaction contained 1 ng/µL cDNA and the concentrations of 
primers and probes were 900 nM and 225 nM, respectively.  
Gene Probe start length Tm 
MDR1 5`-AAGCTGTCAAGGAAGCCAATGCCTATGACTT-3` 1929 31 bp 69.0 °C 
MRP1 5`-CCTCCACTTTGTCCATCTCAGCCAAGAG-3` 2267 28 bp 69.0 °C 
MRP2 5`-CTCAATATCACACAAACCCTGAACTGGCTG-3` 3773 30 bp 68.0 °C 
MRP3 5`-CCAACCGGTGGCTGAGCATCG-3` 3608 21 bp 69.0 °C  
MRP4 5`-CAAACCGAAGACTCTGAGAAGGTACGATTCCT-3` 2094 32 bp 68.4 °C 
MRP5 5`-CTGACGGAAATCGTGCGGTCTTGG-3` 804 24 bp 69.0 °C 
Villin 5`-TCATCAAAGCCAAGCAGTACCCACCAAG-3` 977 28 bp 69.2 °C 
GAPDH 5`-CGCCTGGTCACCAGGGCTGC-3` 79 20 bp 69.0 °C 
BCRP 5`-CCATTGCATCTTGGCTGTCATGGCTT-3` 1883 26 bp 69.4 °C 
ASBT 5`-TTCAGCTCTCCTTCACTCCTGAGGAGCTC-3` 1419 29 bp 69.0 °C 
PPARα 5`-AGGCTGCAAGGGCTTCTTTCGGC-3` 570 23 bp 69.0 °C 
     Gene Forward Primer start length Tm 
MDR1 5`-CTGTATTGTTTGCCACCACGA-3` 1854 21 bp 58.0 °C  
MRP1 5`-GGGCTGCGGAAAGTCGT-3` 2236 17 bp 58.0 °C 
MRP2 5`-ACTGTTGGCTTTGTTCTGTCCA-3` 3746 22 bp 58.4 °C 
MRP3 5`-GGTGGATGCCAACCAGAGAA-3` 3567 20 bp 59.0 °C 
MRP4 5`-AAGTGAACAACCTCCAGTTCCAG-3` 2026 23 bp 58.3 °C 
MRP5 5`-CTGCAGTACAGCTTGTTGTTAGTGC-3` 768 25 bp 59.0 °C 
Villin 5`-CATGAGCCATGCGCTGAAC-3` 957 19 bp 59.9 °C 
GAPDH 5`-GGTGAAGGTCGGAGTCAACG-3` 42 20 bp 59.0 °C 
BCRP 5`-CAGGTCTGTTGGTCAATCTCACA-3` 1859 23 bp 58.7 °C 
ASBT 5`-ACGCAGCTATGTTCCACCATC-3` 1397 21 bp 59.0 °C  
PPARα 5`-CATTACGGAGTCCACGCGT-3` 547 19 bp 58.0 °C 
     Gene Reverse Primer start length Tm 
MDR1 5`-AGGGTGTCAAATTTATGAGGCAGT-3` 1992 24 bp 59.0 °C 
MRP1 5`-AGCCCTTGATAGCCACGTG-3` 2315 19 bp 57.0 °C 
MRP2 5`-CAACAGCCACAATGTTGGTCTCTA-3` 3845 24 bp 60.0 °C 
MRP3 5`-GCAGTTCCCCACGAACTCC-3` 3651 19 bp 59.0 °C 
MRP4 5`-GGCTCTCCAGAGCACCATCT-3` 2144 20 bp 58.0 °C 
MRP5 5`-TCGGTAATTCAATGCCCAAGTC-3` 860 22 bp 59.8 °C  
Villin 5`-TCATTCTGCACCTCCACCTGT-3` 1028 21 bp 59.2 °C 
GAPDH 5`-ACCATGTAGTTGAGGTCAATGAAGG-3` 164 25 bp 59.0 °C 
BCRP 5`-TCCATATCGTGGAATGCTGAAG-3` 1936 22 bp 58.7 °C 
ASBT 5`-GCGGGAAGGTGAATACGACA-3` 1469 20 bp 60.0 °C 
PPARα 5`-ACACCAGCTTGAGTCGAATCG-3` 616 21 bp 59.0 °C 
 
Table 2.1: Sequence, starting position, length (base pairs), and melting temperature of the primers and 
probes that were used for TaqMan analysis. 
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Primers and probes (Table 2.1) were designed according to the guidelines of Applied 
Biosystems with help of the Primer Express 2.0 software. Primers were synthesized by 
Invitrogen (Basel, Switzerland), probes by Eurogentec (Seraing, Belgium). 
All samples in this thesis were run in triplicates. Not reverse transcribed RNA served as negative 
control. No significant amplification was observed in these samples. 
In Chapter 3.1 to 3.4 for each sample, the number of gene transcripts (ASBT, BCRP, MDR1, 
MRP1-5, PPARα) and the number of villin transcripts were determined. By calculating the ratio 
of gene/villin mRNA, the gene expression was normalized to the enterocyte content. 
Determination of villin, an enterocyte specific, constitutively expressed protein can be used to 
control for variation of enterocyte content in biopsies (Lown et al 1997, Taipalensuu et al 2001). 
In Chapter 5 gene expression of MDR1, BCRP, MRP1-5 was normalized to GAPDH, a gene 
which occurs ubiquitary in human tissues. 
 
2.1.3 Generation of cDNA standards for absolute mRNA quantification 
In order to generate standard curves gene-specific cDNA fragments with known concentrations 
as standards were used. These standards serve as a template during the real-time PCR 
because they cover the TaqMan primer/probe area and therefore they are amplified similar to 
the cellular reverse transcribed mRNA of the appropriate gene. Standards were obtained by 
PCR amplification using primers that anneal outside the area where the TaqMan primers anneal 
on the template. Since MDR1, MRP1-5, Villin, and ASBT are expressed in Caco-2 cells and 
BCRP is expressed in BB19 cells, reverse transcribed RNA of these cell lines as a template for 
PCR amplification was used. Each reaction contained 25 ng cDNA and 300nm of each primer in 
a total reaction volume of 25µL. The primers (Table 2.2) were designed using the primer express 
software 2.0 (Applied Biosystems) and were manufactured by Invitrogen (Basel, Switzerland). 
The components of the PCR reaction (AmpliTaq Gold, 10x PCR buffer, dNTPs, MgCl2) were 
purchased form Applied Biosystems. Thermal cycling was conducted using a Mastercycler 
personal from Eppendorf (Hamburg, Germany) and an annealing temperature of 55°C was 
used. The PCR products were purified by running a 1.5% agarose gel (TAE buffer, 100V, 50 
min) and by a subsequent gel extraction (gel extraction kit, Qiagen).  
The obtained standards were quantified using the PicoGreen® dsDNA quantitation kit according 
to the manufacturers protocol (Molecular Probes, Eugene, OR). The PicoGreen® reagent is an 
ultrasensitive fluorescent nucleic acid stain for quantitating double-stranded DNA using 
bacteriophage lambda DNA as a standard. The amount of cDNA in the sample was expressed 
as ng DNA per mL. 
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Additionally, the purified and quantified PCR products were analysed by sequencing (Microsynth 
GmbH, Balgach, Switzerland). The received sequences were aligned to the genes of interest 
using the BLAST program (http://www.ncbi.nlm.nih.gov/BLAST) in order to confirm the identity of 
the PCR products. For further calculations the molecular weights of the cDNA fragments (Table 
2.3) were determined on the basis of the corresponding sequence with the help of a biopolymer 
calculator (http://paris.chem.yale.edu/extinct.frames.html). 
primer sequence start length Tm 
MDR1 forward 5`-ACAGTCCAGCTGATGCAGAGG-3`  1730  21 bp  59.1 °C 
MDR1 reverse 5`-CCTTATCCAGAGCCACCTGAAC-3`  2150  22 bp  58.7 °C 
MRP1 forward 5`-CACACTGAATGGCATCACCTTC-3`  2173  22 bp  59.1 °C 
MRP1 reverse 5`-CCTTCTCGCCAATCTCTGTCC-3`  2489  21 bp  59.8 °C 
MRP2 forward 5`-CCAATCTACTCTCACTTCAGCGAGA-3`  3509  25 bp  60.0 °C 
MRP2 reverse 5`-AGATCCAGCTCAGGTCGGTACC-3`  3981  22 bp  60.5 °C 
MRP3 forward 5`-TCTATGCAGCCACATCACGG-3`  3419  20 bp  59.3 °C 
MRP3 reverse 5`-GTCACCTGCAAGGAGTAGGACAC-3`  3746  23 bp  58.8 °C 
MRP4 forward 5`-AAGTGAACAACCTCCAGTTCCA-3`  2026  22 bp  57.3 °C 
MRP4 reverse 5`-CCGGAGCTTTCAGAATTGAC-3`  2543  20 bp  56.1 °C 
MRP5 forward 5`-CTAGAGAGACTGTGGCAAGAAGAGC-3`  570  25 bp  59.0 °C 
MRP5 reverse 5`-AAATGCCATGGTTAGGATGGC-3`  902  21 bp  59.6 °C 
Villin forward 5`-AGAAAGCCAATGAGCAGGAGAA-3`  926  22 bp  59.1 °C 
Villin reverse 5`-ATGGATGTGGCATCGAACTTC-3`  1163  21 bp  58.5 °C 
GAPDH forward 5`-ACATCGCTCAGAACACCTATGG-3` 16 22 bp 58.0 °C 
GAPDH reverse 5`-GCATGGACTGTGGTCATGAGTC-3` 572 22 bp 59.0 °C 
BCRP forward 5'-TTTCAGCCGTGGAACTCTTT-3'  1529  20 bp  56.2 °C 
BCRP reverse 5'-TGAGTCCTGGGCAGAAGTTT-3'  1990  20 bp  56.0 °C 
ASBT forward 5`-CATCTCTGGTTGCTCTCGTTGTTC-3`  1098  24 bp  61.1 °C 
ASBT reverse 5`-TGATGTCTACTTTTCGTCAGGTTGAA-3`  1651  26 bp  60.0 °C 
PPARα forward 5`-AGGAAGCTGTCCTGGCTCAG-3` 381 20 bp 58.2 °C 
PPARα reverse 5`-CGTCCAAAACGAATCGCG-3` 734 18 bp 59.8 °C 
 
Table 2.2: Sequence, starting position, length (base pairs), and melting temperature of the primers that 
were used for the generation of gene-specific cDNA standards. 
 
amplicon gene name accession number length molecular weight 
MDR1 ABCB1 NM_000927  421 bp 130377.2 g/mol 
MRP1  ABCC1 NM_004996  317 bp 97797.4 g/mol 
MRP2  ABCC2 NM_000392  473 bp 145684.6 g/mol 
MRP3  ABCC3 NM_020038  328 bp 100912.6 g/mol 
MRP4  ABCC4 NM_005845  518 bp 159304.6 g/mol 
MRP5  ABCC5 NM_005688  333 bp 102594.6 g/mol 
Villin VIL1 NM_007127  238 bp 73486.6 g/mol 
GAPDH GAPDH M17851 557 bp 171314.4 g/mol 
BCRP ABCG2 NM_004827  462 bp 142064.4 g/mol 
  40 
ASBT SLC10A2 NM_000452  554 bp 170455.8 g/mol 
PPARα PPARA BC000052 353 bp 109082.8 g/mol 
 
Table 2.3: Gene name, gene bank accession number, length (base pairs) and molecular weight of the 
PCR amplicons that were used as standards for TaqMan analysis. 
 
2.1.4 Standard curve method 
A standard curve for each gene on each plate is essential for accurate quantification of mRNA 
transcript numbers. The standard curves were generated by a serial dilution of cDNA standard 
solutions with known amount of PCR template. To obtain standard curves that span the range 
above and below the amount of the unknown samples, the quantified standard solutions were 
first analysed in TaqMan assays and adapted by further dilutions (= standard dilution in 
equation 1) so that the obtained curves were adequate. 
Linear standard curves were composed by plotting the Ct values of the standards against the log 
of their corresponding serial dilution factor. Slope and Y-intercept of the standard curve line were 
then calculated by linear regression. By measuring the Ct value of the unknown sample under 
the same conditions, its corresponding serial dilution factor (= X in equation 1) could then be 
determined. 
Based on this serial dilution factor (X) the number of cDNA molecules of the analysed gene in 
the sample (transcript number) could be estimated. Therefore, the number of cDNA fragments in 
the applied standard solution (standard 1) was calculated and subsequently multiplied with the 
serial dilution factor (X) of the sample. Usually, the transcript number is normalised to 1 µg RNA. 
The following equation (equation 1) shows how the transcript number per µg RNA was 
calculated. 
 
C x V x N x X 
Transcript number µg total RNA =  
standard dilution x MW x 1x1012 
 
Equation 1: C (ng/mL) is the concentration of the standard determined with the PicoGreen® assay. V 
(µL) is the volume of sample cDNA that contains 1 µg of reverse transcribed RNA. This is 100 µL for the 
common cDNA concentration of 10 ng/µL. N is Avogadro`s number (6.022x1023 molecules per mol). X is 
the serial dilution factor of the sample determined with the standard curve. The standard dilution 
describes how-fold the standard 1 has been diluted for adapting the standard curve. MW (g/mol) is the 
molecular weight of the standard. 1x1012 accounts for conversions of units. 
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2.2 Immunohistochemical assessment of BCRP and ASBT in human intestinal biopsies 
Immunohistochemistry was used to evaluate the expression of the apical sodium-dependent bile 
acid transporter (ASBT/SLC10A2) and of breast cancer resistance protein (BCRP/ABCG2) in 
human intestinal tissue.  
For immunohistochemical assessment of ASBT expression in human intestinal tissue a 
polyclonal rabbit anti-human ASBT (generous gift from Dr. P.A. Dawson, Wake Forest University 
Baptist Medical Center, Winston-Salem, NC) was used. This antibody was raised against the 
carboxyl-terminal 39 amino acids of human ASBT that was expressed as a glutathione S-
transferase-ASBT fusion protein. The human ASBT antibody has been previously used to 
measure ASBT protein expression in human ileal biopsies. 
BCRP monoclonal antibody BXP-21 was purchased from Alexis Biochemicals (Lausen, 
Switzerland).   
 
Human intestinal tissue was mounted in OCT compound (Sakura Finetek, Zooterwoude, The 
Netherlands), frozen in liquid nitrogen and stored at -70°C. Sections (5 µm) of human intestine 
were air dried overnight and a periodate-lysine-paraformaldehyde solution (3%) was used for 
post-fixation. Then the sections were washed with washing solution (TBS/NaCl, Tween 0.05%) 
and incubated with normal horse serum (for BCRP incubation) or with goat serum (for ASBT 
incubation) for 30 min at room temperature as blocking solution. Then, the tissue sections were 
incubated either with a 1:40 dilution of the BCRP monoclonal antibody BXP-21 (Alexis 
Biochemicals, Lausen, Switzerland) or with a 1:400 dilution of the polyclonal rabbit anti-human 
ASBT overnight at 4°C. 
Samples were washed three times with washing solution and incubated with the horse 
antimouse IgG secondary antibody (for BCRP incubation) or with the goat anti-rabbit IgG 
secondary antibody (for ASBT incubation) for 30 min at room temperature, respectively. After 
three washes with the washing solution, a perhydral solution (H2O2 (0.3%), sodium azide (0.1%) 
in PBS) was used to destroy the endogenous peroxidase activity. The staining was performed 
with the avidin/biotinylated enzyme complex (ABC method) according to the manufacturer`s 
instructions (Vectastain, Elite kit, Vector Laboratories, Burlingane, CA, USA). For detection 3-
amino-9-ethylcarbazole (AEC), which forms a red end product, was used (Biogenex, San 
Ramon, CA, USA).  
Sections, which served as negative controls were incubated only with the horse antimouse IgG 
or with the goat anti-rabbit IgG secondary antibody, respectively. Biopsies from normal terminal 
ileum were used as positive control. 
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2.3 Determination of bilirubin and bile acid plasma concentrations 
Blood samples from subjects were obtained shortly before endoscopic procedure. Bilirubin 
plasma concentrations were measured by a modified Malloy-Evelyn method (BIL-T, Roche 
Diagnostics, Mannheim, Germany).  
 
Fasting plasma levels of bile acids were extracted with Bond-Elut C18 cartridges (Analytichem 
International, San Diego, CA), solvolysis was performed to cleave sulfate groups and enzymatic 
hydrolysis was performed to deconjugate bile acid amidates. Deconjugated bile acids were 
isolated by extraction on Lipidex 1000 (Packard Instruments, Groningen, The Netherlands) and 
were then methylated and trimethylsilylated for gas chromatography. Capillary gas 
chromatography was performed using a Carlo Erba Fractovap 4160 gas-chromatograph (Carlo 
Erba Instruments, Hofheim, Germany). Bile acid derivatives were separated on a fused silica 
capillary CP Sil 19 CB column coated with chemically bonded OV-1701 (25 m x 0.33 mm, 
Chrompack, Middelburg, The Netherlands). Hydrogen was the carrier gas (P=0.6 kg/cm2). A 
temperature program from 140°C to 270°C with 8°/min  was started after on-column injection. 
Eluting bile acid derivates were detected by a flame ionization detector. Fasting plasma samples 
were stored at - 20°C until analyzed. 
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3.1.1 Abstract 
The apical sodium dependent bile acid transporter ASBT (SLC10A2) contributes substantially to 
the enterohepatic circulation of bile acids by their reabsorption from the intestine. In the rat, its 
adaptive regulation was observed in the kidneys, cholangiocytes and terminal ileum after bile 
duct ligation. Whether an adaptive regulation of the human intestinal ASBT exists during 
obstructive cholestasis is not known.  
Human ASBT mRNA expression along the intestinal tract was analyzed by real time PCR in 
biopsies of 14 control subjects undergoing both gastroscopy and colonoscopy. Their duodenal 
ASBT mRNA expression was compared to 20 patients with obstructive cholestasis. Additionally, 
in 4 patients with obstructive cholestasis, duodenal ASBT mRNA expression was measured 
after reconstitution of bile flow.  
Normalized ASBT expression in control subjects was highest (mean arbitrary units± SEM) in the 
terminal ileum 1010 ± 330. Low ASBT expression was found in the colonic segments (8.3±5, 
4.9±0.9, 4.8±1.7 and 1.1±0.2, ascending, transverse, descending, and sigmoid colon, 
respectively). Duodenal ASBT expression of control subjects was found with 171.8±20.3 at 
about four fold higher levels when compared to 37.9±6.5 (p<0.0001) in patients with obstructive 
cholestasis. Individual ASBT mRNA expression was inversely correlated with bile acid and 
bilirubin plasma concentrations. In 4 cholestatic patients average ASBT mRNA increased from 
76±18 before to 113±18 after relief of cholestasis (NS). Immunohistochemical assessment 
indicates that ASBT protein is expressed on the apical surface of the duodenal epithelial cells. 
Obstructive cholestasis in humans leads to down-regulation of ASBT mRNA expression in the 
distal part of the human duodenum.  
 
3.1.2 Introduction 
Bile acids are amphipathic steroidal compounds derived from the enzymatic catabolism of 
cholesterol in the liver by cytochrom P450 isoform 7A1 (CYP7A1). In the small intestine, bile 
acids emulsify dietary fats and lipid-soluble vitamins. They participate in the regulation of 
pancreatic secretion and the release of gastrointestinal peptides (Koop et al., 1996). Through a 
coordinated action of several transport proteins expressed in hepatocytes, cholangiocytes as 
well as in enterocytes and in proximal tubular cells of the kidney, an efficient enterohepatic 
circulation of bile acids is maintained (Meier and Stieger, 2002). One of these transport proteins, 
the apical sodium-dependent bile acid transporter ASBT (SLC10A2) has been detected in the 
ileum, cecum, and kidney (Craddock et al., 1998) and mediates the uptake of bile acids from the 
lumen of the intestine, from renal tubules and from cholangiocytes. ASBT is a 348 amino acid 
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protein that transports conjugated and unconjugated bile acids with a high efficiency (Craddock 
et al., 1998). Subjects with mutations in the ASBT gene suffer from congenital diarrhea and 
steatorrhea, due to bile acid malabsorption (Oelkers et al., 1997). Pharmacological inhibition of 
ASBT leads to interruption of enterohepatic circulation of bile acids with changes in the 
cholesterol and bile acid homeostasis (Lewis et al., 1995; Huff et al., 2002; West et al., 2002; 
Bhat et al., 2003; Telford et al., 2003). Adaptive induction of ASBT mRNA expression, 
transporter protein and transport activity was observed in cholic acid fed rats (Stravitz et al., 
1997), whereas decreased ASBT expression was found in the ileum of bile duct ligated 
rats.(Sauer et al., 2000) In addition in Wistar rats, a marked reduction of ASBT protein 
expression was observed in microsomal membrane fractions from whole kidney after ligation of 
the common bile duct (CBDL) with the consequence of increased urinary bile acid excretion. 
These results indicate that ASBT is adaptively regulated in different tissues during obstructive 
cholestasis in the rat.  
Lanzini et al. (Lanzini et al., 2003) studied the effects of cholestasis on intestinal bile acid 
transport in 14 subjects with chronic cholestasis due to primary biliary cirrhosis (PBC) before 
and during ursodeoxycholic acid (UDCA) administration. Prolonged retention of the bile acid 
analogue 75Se-homocholic acid taurine (75SeHCAT) in patients with PBC was observed 
compared to healthy controls and patients with Crohn`s disease. The retention of 75SeHCAT 
decreased with UDCA treatment inferring that luminal bile acid levels might be involved in the 
regulation of ASBT gene regulation.  
Virtually all bile salt transporter systems are subject to extensive regulation, mainly at the level of 
gene transcription. These regulatory mechanisms represent adaptive responses to intracellular 
accumulation of bile salts and other amphipathic molecules. However, little is known about 
adaptive regulation of ASBT expression in humans. The aim of this study was therefore to 
investigate the expression of ASBT in the duodenum of healthy subjects and compare the 
results to patients with obstructive cholestasis. Because direct analysis of the ASBT gene 
expression in samples from the terminal ileum can not be performed in humans with obstructive 
cholestasis due to obvious ethical reasons, we analyzed in the first part of this study ASBT 
mRNA expression in healthy subjects in different segments of the human intestine. We found 
that ASBT mRNA is also expressed in the duodenum, however to a lesser extent than in the 
terminal ileum.  
Additionally, we analyzed the gene expression of multidrug resistance associated protein 3 
(MRP3), which is expressed on the basolateral membrane of the enterocyte (Rost et al., 2002) 
and which is capable of transporting bile salts (Hirohashi et al., 2000), as well as the expression 
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of multidrug resistance associated protein 2 (MRP2). Human duodenal MRP2 protein expression 
was downregulated during cholestasis (Dietrich et al., 2004). Biopsies of the duodenum of 
patients with obstructive cholestasis were obtained during a therapeutic endoscopic retrograde 
cholangiopancreatography (ERCP).  
 
3.1.3 Patients and Methods 
Patients 
14 healthy subjects (7 males, 7 females) were enrolled into the first part of the study after giving 
informed consent. The indication for combined upper and lower GI tract endoscopy was a 
cancer screening programme. Biopsies were obtained from the duodenum, the terminal ileum 
and from different defined regions of the colon. In the second part of the study, 20 cholestatic 
patients were enrolled after giving written informed consent. Biopsies were obtained from the 
duodenum in these patients. Of 10 patients with obstructive tumours, four had carcinoma of the 
pancreatic head, 4 had cholangiocarcinoma (Klatskin tumour) and two had metastatic diseases. 
10 patients had benign diseases (8 patients with choledocholithiasis and two patients with a 
benign stenosis of the common bile duct). Obstructive jaundice was defined 1) on the basis of 
chemical parameters (bilirubin, γ-glutamyltransferase, and alkaline phosphatase) and 2) on 
imaging procedures (ultrasound and ERCP) demonstrating a dilated bile duct system. All control 
patients had normal values of the above cited parameters. Patients were only included, if the 
subject was not taking any medication known to affect ASBT, MRP2 as well as MRP3 
expression. Demographic details are given in Table 1. 
Table 1: Patient characteristics of the two study groups 
Characteristics Icteric patients Controls p-value 
  (n=20) (n=14)   
Age mean (±SEM) 67.4 (±2.8) 59.8 (±2.7) NS 
BMI (kg/m2) (±SEM) 24.1 (±0.8)  28.4 (±1.6) p= 0.015 
Gender 10 males and 10 females 7 males and 7 females NS 
Diagnosis 10 T/10 BS 3G/ 3E/ 8U   
Bilirubin (µmol/l) 235 (42-640) 11 (5-17) P< 0.001 
Bile acids (µmol/l) 122.6 (20.5-401) 1.7 (0.5-3.2) P< 0.001 
 
T = tumor, BS = biliary stone; G = mild gastritis, E = mild esophagitis, U = macroscopically unaffected 
mucosa 
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Material 
All chemicals were of highest quality available and were obtained from commercial sources. 
 
Real-time polymerase chain reaction analysis of human ASBT, MRP2, MRP3, PPAR-α and 
Villin (VIL1) mRNA (TaqMan assay) were shown in Chapter 2 
 
Primers and Probes for TaqMan Analysis see Table 2.1 
 
Statistical analysis 
All values were expressed as means ± SEM. The impact of different parameters (bilirubin and 
bile acid concentration, body-mass index, age and sex) on the variability of ASBT expression 
was investigated by multi-linear regression analysis. Icteric patient’s ASBT expression was 
compared to that of healthy controls by analysis of variance (ANOVA). Regional ASBT mRNA 
expression was compared with the expression in duodenum by repeated measurement ANOVA 
with linear contrasts. Correlation of serum bilirubin and bile acid concentrations was done using 
Spearman’s rank correlation coefficient (rho). Differences in demographic characteristics 
between icteric patients and controls were done by ANOVA of Chi-square test, as appropriate. 
All comparisons were performed as two-sided comparisons using the SPSS for Windows 
software (version 12.0). Level of significance was p<0.05 
 
3.1.4 Results 
 
3.1.4.1 Expression pattern of ASBT mRNA in the human intestine 
Human ASBT mRNA expression was studied in 14 control subjects (7 women and 7 men), who 
were undergoing a combined gastroscopy and colonoscopy. The results were normalized by 
calculation of the ASBT/villin ratio. The normalized ASBT expression ± SEM (arbitrary units) was 
171.8 ± 20.3 in the duodenum, 1010 ± 330 in the terminal ileum, 8.3 ± 5 in the ascending colon, 
4.9 ± 0.9 in the transverse colon, 4.8 ± 1.7 in the descending colon and 1.1± 0.2 in the sigmoid 
colon, respectively (Figure 1).  
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Figure 1: mRNA expression of ASBT in different gut segments. Data represents means (±SEM) of 
biopsies from 14 healthy subjects 
 
3.1.4.2 Duodenal expression of ASBT mRNA and PPARα mRNA 
An adaptive regulation of ASBT expression in obstructive cholestasis was investigated by 
quantification of ASBT mRNA levels in duodenal biopsies of 20 patients with obstructive 
cholestasis and compared to the levels obtained in 14 control subjects. As shown in Figure 2, 
ASBT mRNA expression (ASBT/villin ratio ± SEM) was about four-fold lower in patients with 
obstructive cholestasis (37.9 ± 6.5) when compared with control subjects (171.8 ± 20.3) (p < 
0.001).  
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Figure 2: Comparison of ASBT mRNA expression in patients with obstructive cholestasis (N = 20) vs. 
control subjects (N = 14) and follow up patients (N = 4). Data represent means ± SEM. Scatter plot: lines 
connect individual ASBT mRNA expression pre- and post reconstitution of bile flow in 4 follow-up patients. 
 
Patients with obstructive cholestasis due to a tumour showed a trend for lower ASBT mRNA 
expression when compared to patients with a benign aetiology of obstructive cholestasis (31.2 ± 
7.3 for tumour induced and 44.6 ± 10.8 benign obstruction); the difference did, however, not 
reach statistical significance. The plasma bilirubin levels were 301.6 ± 64.9 and 112.6 ± 20.0 
mmol/L (P = 0.02) and bile acid levels were 168.4 ± 45.3 and 76.8 ± 22.8 µmol/L (NS) for 
patients with and without tumours, respectively.  
PPARα mRNA expression was not significantly different between cholestatic patients and 
controls. 
      
3.1.4.3 Correlation of duodenal ASBT mRNA expression with bilirubin and bile acid 
plasma concentration 
Bilirubin and bile acid plasma concentrations were inversely correlated with ASBT mRNA 
expression (rho = -0.863, p < 0.001 and rho= -0.722, p<0.001, respectively). The correlation with 
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ASBT mRNA expression was similar for bilirubin and bile acid concentrations. Using ASBT 
mRNA expression, an almost perfect separation was obtained between icteric patients and 
healthy controls (Figure 3A and B).  
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Figure 3A and 3B: Individual correlation of bilirubin (3A) and bile acid (3B) plasma concentrations with 
ASBT mRNA expression in patients with obstructive cholestasis (•) and control subjects (Ο). Data 
represent means ± SEM. Arrows connect individual values pre- and post reconstitution of bile flow in 4 
follow-up patients. 
 
3.1.4.4 Effect of reconstitution of bile flow on ASBT mRNA expression  
In 5 of the included 20 icteric patients a follow-up gastroscopy could be performed between 10 
and 34 weeks after reconstitution of bile flow (follow-up endoscopy was only performed when 
medically indicated). Three of the five patients received stents into the common bile duct, two 
patients had a Whipple-operation, one due to a tumour in the head of the pancreas and one due 
to a cholangiocarcinoma. The patient with Whipple operation due to a tumor in the head of the 
pancreas could not be included in the follow-up analysis, because duodenal biopsies could not 
be obtained after a complete duodenopancreatectomy. In the patient with cholangiocarcinoma, 
only a partial duodenopancreatectomy was performed, so duodenal biopsies could be obtained 
in the follow-up endoscopy.  
At follow-up endoscopy the bilirubin and bile acid plasma concentrations had normalized in all 
patients and 3 of 4 patients showed an increased expression of ASBT mRNA compared to the 
baseline value obtained. These three follow-up patients with bilirubin (bile acid) plasma 
concentrations of 373 (431), 170 (204) and 115 (170) µmol/l before endoscopic intervention 
  52 
showed an increase in ASBT expression from 73 to 103, 29 to 68 and 71 to 157 after 
reconstitution of bile flow, respectively. One patient, who had a bilirubin (bile acid) level of 65 
(32.2) µmol/l before intervention and 24 (14.5) µmol/l after reconstitution of bile flow showed an 
ASBT expression of 130 before intervention, which decreased slightly to 122 after reconstitution 
of bile flow. (n=4). The difference in the ASBT expression before 76 ± 18 and after reconstitution 
113 ± 18 of bile flow for these four follow up patients was not significant (paired t-test; p = 0.15). 
 
3.1.4.5 Immunohistochemistry of ASBT 
Immunohistochemistry analysis in healthy subjects revealed a clear staining of ASBT in ileal and 
duodenal mucosa (Figure 4A and B, respectively). Staining of duodenal mucosa was clearly less 
intense than that from ileal tissue. In the duodenal mucosa of icteric patients, staining for ASBT 
was almost completely abolished (Figure 4C). After reconstitution of bile flow a more intense 
staining was found in the same tissue (Figure 4D). 
 
3.1.4.6 Duodenal expression of MRP2 mRNA and MRP3 mRNA 
Additionally we investigated, whether there is also an adaptive regulation of MRP2 and MRP3 
mRNA expression in the distal part of the duodenum.  
Patients with obstructive cholestasis showed a significantly lower MRP2 mRNA expression (0.21 
± 0.02) compared to control subjects (0.32 ± 0.03, p= 0.004). After reconstitution of bile flow in 4 
patients with obstructive cholestasis, MRP2 expression increased to 0.28 ± 0.02 (NS). No 
difference between patients with obstructive cholestasis and control subjects was observed with 
regard to the MRP3 expression (data not shown). 
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3.1.5 Discussion 
 
Bile acids undergo extensive enterohepatic and cholehepatic circulation through a coordinated 
action of several transport proteins in the hepatocytes, cholangiocytes and enterocytes (Trauner 
and Boyer, 2003). The uptake of bile acids at the apical membrane of enterocytes by the apical 
sodium dependent bile acid transporter ASBT (SLC10A2) reflects an important mechanism for 
the enterohepatic circulation of bile acids. Human ASBT is an efficient transport system for 
conjugated and unconjugated bile acids (Craddock et al., 1998). In the present study we were 
able to show that human ASBT mRNA and protein are expressed in the duodenum of the 
A B 
C D 
Figure 4 A-D: Immunohistochemical localization of ASBT protein on the apical membrane 
of the ileum and duodenum of humans using a polyclonal rabbit anti-human ASBT 
antibody: clear staining of ileal (4A) and duodenal epithelial cells (4B) of control subjects. 
Almost abolished staining of duodenal epithelial cells in a patient with obstructive 
cholestasis before (4C) and restored duodenal staining after (4D) reconstitution of bile 
flow (all pictures at 200-fold magnification). 
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human intestine, but to a lesser extent than in the terminal ileum. In addition, a significant down-
regulation of duodenal ASBT mRNA expression could be demonstrated in patients with 
complete or near complete obstruction of the bile duct when compared to control subjects. 
Finally, restoring bile flow to the duodenum increased ASBT mRNA expression in a 
subpopulation of patients with bile duct obstruction. 
The down-regulation of human duodenal ASBT mRNA may be compared with the adaptive 
response of bile acid transport proteins during obstructive cholestasis, in the terminal ileum, the 
kidney, as well as in the cholangiocytes of the rat (Sauer et al., 2000; Lee et al., 2001). In 
addition to the down-regulation of ASBT in the terminal ileum, the intestinal absorption rate of 
taurocholate in bile duct-ligated rats was lower and the absorption rate was inversely correlated 
to serum bile acid concentrations when compared to sham operated rats (Sauer et al., 2000). 
Patients with mutations in the ASBT gene can suffer from congenital diarrhoea and steatorrhea, 
which is explained by an interrupted enterohepatic bile acid circulation (Oelkers et al., 1997). 
Further clinical data indicate that in patients with primary sclerosing cholangitis, biliary 
enrichment of ursodeoxycholic acid (UDCA) decreases with increasing cholestasis (Stiehl et al., 
1995). Moreover, in patients with bile duct obstruction and external biliary drainage intestinal 
absorption of UDCA was decreased, before relief of cholestasis (Sauer et al., 1999). These data 
suggest that in humans intestinal bile acid absorption is reduced during obstructive cholestasis.  
What factors influence ASBT gene expression in the enterocyte is largely unknown. Animal 
studies suggest that luminal bile acids might be one such regulatory factor. Reduction of 
intestinal bile acid concentration during fasting (Dumaswala et al., 1994), after biliary diversion 
(Higgins et al., 1994) or bile duct ligation (Dumaswala et al., 1996) is accompanied by a 
decrease in ileal bile acid transport. Stravitz et al. could demonstrate that increasing intestinal 
bile acid concentrations by cholic acid feeding leads to an increase in the sodium dependent 
transport rate (Stravitz et al., 1997). Furthermore, adaptive induction of Asbt mRNA levels and 
transporter protein as well as increased Asbt transport activity by cholic acid fed rats was 
documented (Stravitz et al., 1997). 
In contrast to these observations, other authors have demonstrated in rats that the ileal 
taurocholate absorption rate correlated inversely to serum bile acid concentrations after bile duct 
ligation and after biliary diversion compared to sham-operated animals (Sauer et al., 2000). The 
authors concluded that cholestasis leads to decreased and biliary diversion to increased active 
ileal absorption of taurocholate, in which the systemic bile acid load seems to be the decisive 
factor. In the kidney bile acid excretion in the urine increased progressively in both cholestatic 
animal models but also in clinical cholestatic disorders (Stiehl et al., 1985; Lee et al., 2001). In 
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Wistar rats, a marked reduction in Asbt protein expression in microsomal membrane fractions 
from whole kidney after a common bile duct ligation (CBDL) was observed resulting in reduced 
levels of Asbt expression on the luminal membrane of the proximal tubule of the kidney, a 
change that is associated with a diminished capacity to reabsorb bile acids from the glomerular 
filtrate (Lee et al., 2001). In the same study, an up-regulation of Mrp2 protein expression on the 
apical membrane of the rat renal proximal tubule was shown. MRP2 is associated with an 
increased ability to excrete divalent organic anions such as bile salt sulfates and glucuronides 
(bilirubin) that accumulate during cholestasis and would therefore facilitate extrahepatic 
pathways for bile acid and bilirubin excretion during cholestasis. This adaptive response of Asbt 
and Mrp2 in the kidney of the rat does not seem to be regulated by luminal bile acids.  
 
Here we could show that ASBT mRNA expression correlated inversely with bilirubin as well as 
with bile acid plasma concentrations, which were both used as a marker for obstructive 
cholestasis.  
Bile acids are synthesized from cholesterol in the liver; their production is a major mechanism of 
cholesterol elimination and important for the maintenance of cholesterol homeostasis (Vlahcevic 
et al., 1999). The down-regulation of ASBT expression in obstructive cholestasis might therefore 
be of clinical interest. In a previous publication, it was shown that inhibition of the ileal bile acid 
transport with SC-435, a competitive inhibitor of ASBT, lowered plasma cholesterol levels 1) by 
inactivating the hepatic farnesoid x receptor and 2) by stimulating the cholesterol 7α-hydroxylase 
(CYP7A1) (Li et al., 2004). This cytochrome is the rate-limiting enzyme of chenodeoxycholic acid 
synthesis. It is located in the endoplasmic reticulum of the hepatocyte. In patients with biliary 
obstruction, a rise of serum 7α-hydroxycholesterol was observed after biliary drainage (Okamoto 
et al., 1994). The 7α-hydroxylation rate was significantly lower for patients with obstructive 
cholestasis when compared to healthy subjects (Bertolotti et al., 2001). These data suggest that 
in case of a substantial bile acid malabsorption the activity of 7α-hydroxylase in the liver and the 
synthesis of bile acids is increased. Other authors suggest that inhibition of ASBT with SC-435 
reduces LDL cholesterol and ApoB by enhanced plasma clearance of LDL ApoB (Huff et al., 
2002; Telford et al., 2003). Treatment of Caco-2 cell monolayers with 25-hydroxycholesterol 
significantly inhibited Na+-dependent 3H-taurocholate uptake. The inhibition in hASBT activity 
was associated with reduction in both the level of hASBT mRNA and its promoter activity (Alrefai 
et al., 2004). ASBT protein expression did not change in rats but rose by 31% in rabbits when 
feeding them with cholesterol (cholest-5-en-3β-ol) (Xu et al., 2000). Administration of SC-435 to 
apo E-/- mice lowered serum total cholesterol by 35% and reduced aortic root lesion area by 
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65%. The authors concluded that specific inhibition of ASBT could be a novel therapeutic 
approach for treatment of hypercholesterolemia resulting in decreased risk for atherosclerosis 
(Bhat et al., 2003). Taken together all these data suggest that the expression of ASBT in the 
enterocyte seems to be an important component in the cholesterol homeostasis and lipid 
metabolism in humans. 
The intracellular factors that influence ASBT gene expression remain largely unknown. One 
potential factor might be the activation of nuclear receptor PPARα, a ligand activated 
transcription factor that regulates the expression of a number of genes involved in peroxisomal 
and mitochondrial β-oxidation of fatty acids. PPARα binds as a heterodimer with the retinoid X 
receptor (RXR) to a peroxisome proliferator-response element (PPRE) located in the promoter 
region of target genes. PPARα was shown to play a critical role in the adaptive response to 
fasting in mice (Kroetz et al., 1998; Kersten et al., 1999; Leone et al., 1999). PPARα also 
influences bile acid composition by induction of the sterol 12α-hydroxylase, which acts at a 
branch-point in the bile acid synthetic pathway by catalizing the conversion of 7α-hydroxy-4-
cholesten-3-one to 7α,12α-dihydroxy-4-cholesten-3-one. This reaction determines the ratio of 
cholic acid to chenodeoxycholic acid (Hunt et al., 2000). In Hepa 1c1c7 cells, which were 
transiently tranfected with an expression plasmid for PPARα and RXRα and a luciferase 
reporter construct containing copies of the PPRE from the rat ACOX gene, an inhibition of 
PPARα reporter gene expression was shown with increasing concentrations of 
chenodeoxycholic acid (CDCA) in the presence or absence of Wy-14,643 (=PPARα ligand) 
(Sinal et al., 2001).  It was concluded that during certain pathophysiological states, where 
intracellular bile acid concentrations might be elevated, effects on PPARα-dependent target 
gene regulation are possible (Sinal et al., 2001). Recently, PPARα was shown to transactivate 
the human ASBT gene (Jung et al., 2002). Incubation of human hepatoma HepG2 cells with 
CDCA resulted in a significant induction of PPARα mRNA levels. In addition, hPPARα gene 
expression was upregulated by taurocholic acid in human primary hepatocytes (Pineda Torra et 
al., 2003). However, no difference between patients with obstructive cholestasis and control 
subjects was observed with regard to duodenal PPARα mRNA expression in our study.     
In a previous study, Dietrich et al demonstrated that obstructive cholestasis promotes down-
regulation of intestinal MRP2 protein expression in rats and humans (Dietrich et al., 2004). The 
reduction was correlated with the duration of cholestasis and was reversible after reconstitution 
of bile flow. In the same study in patients with obstructive cholestasis a non significant decrease 
of MRP2 mRNA expression was detected when compared to control subjects. However, the 
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authors observed that decline of intestinal rat Mrp2 mRNA occurs more slowly and gradually 
than down-regulation of its protein expression. Our results showed a significant down-regulation 
of MRP2 mRNA expression when compared to control subjects and a non significant increase 
after reconstitution of bile flow in 4 patients. One explanation for the down-regulation of MRP2 
gene expression in our study compared to Dietrich et al. (Dietrich et al., 2004) might be higher 
plasma bilirubin concentrations in our patients with obstructive cholestasis, another might be 
duration of cholestasis, which was not clearly stated in both studies and therefore might have 
been different. But also other factors such as food derived compounds or substrates might be 
involved in the regulation of gene expression. For example, it was shown that grapefruit and 
orange juice inhibited the transport by MRP2 (Honda et al., 2004); components of our daily diet, 
such as the flavonoid epicatechin in tea (Vaidyanathan and Walle, 2001), chrysin and its 
metabolites are substrates of MRP2 (Walle et al., 1999). Drugs are unlikely to have contributed 
to the different MRP2 mRNA expression in the present study and the study performed by 
Dietrich et al. (Dietrich et al., 2004) because patients with drugs, which are known to affect 
MRP2 expression, were excluded from both studies. Finally, our data support the results of 
Dietrich et al. (Dietrich et al., 2004), which demonstrate an adaptive down-regulation of duodenal 
MRP2 in patients with obstructive cholestasis. 
MRP3 is expressed on the basolateral membrane in the proximal small bowel (Rost et al., 2002) 
and is capable of transporting bile salts, including taurocholate, glycocholate, 
taurochenodeoxycholate-3-sulfate, taurolithocholate-3-sulfate (Hirohashi et al., 2000). This 
suggests that MRP3 might be an important transporter in the enterohepatic circulation of bile 
acids. However, in the present study we did not observe any difference of human duodenal 
MRP3 gene expression in patients with obstructive cholestasis when compared to control 
subjects. Similarly, no compensatory up-regulation of human duodenal MRP3 expression in 
cholestatic patients was previously described (Dietrich et al., 2004). 
 
In conclusion, human ASBT mRNA is expressed in the small intestine, predominantly in the 
terminal ileum but also, to a lesser extent, in the duodenum. Adaptive down-regulation of ASBT 
and MRP2 mRNA in the duodenum can be observed in patients with obstructive cholestasis, 
when compared to control subjects. Furthermore, the duodenal ASBT mRNA expression levels 
inversely correlate with the bilirubin and bile acid plasma concentrations in patients with 
obstructive cholestasis as well as in control subjects. This adaptive gene regulation may 
represent a mechanism preventing the accumulation of hepatotoxic bile acids in cholestasis. 
After relief of cholestasis, an increase of ASBT mRNA was observed in 3 out 4 patients.  
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3.2.1 Abstract 
Human breast cancer resistance protein (BCRP/ABCG2) is an ABC-transporter that is present 
on the luminal membrane of intestinal epithelial cells and restricts absorption of anticancer drugs 
such as methotrexate, topotecan, mitoxantrone, and doxorubicin. The exact anatomic 
distribution of BCRP along the gastrointestinal (GI) tract has, however, not been determined 
before. The aim of this study was, therefore to investigate BCRP mRNA expression pattern 
along the GI tract in 14 healthy subjects. Furthermore, BCRP duodenal mRNA expression was 
compared with MDR1/ABCB1 mRNA. Additionally, BCRP mRNA expression was investigated in 
two human intestinal cell lines (Caco-2 and LS180). Since previous animal studies have 
suggested sex specific differences in BCRP expression, we analyzed intestinal BCRP 
expression with respect to sex. Biopsies were taken from different gut segments (duodenum, 
terminal ileum and ascending, transverse, descending and sigmoid colon). Gene expression 
was assessed by quantitative real-time PCR (Taqman). BCRP mRNA expression was maximal 
in the duodenum and decreased continuously down to the rectum (terminal ileum 93.7 percent, 
ascending colon 75.8 percent, transverse colon 66.6 percent, descending colon 62.8 percent, 
and sigmoid colon 50.1 percent compared to duodenum, respectively). BCRP expression in the 
duodenum was comparable to MDR1/ABCB1 gene expression. Caco-2 cells showed a 
comparable expression of BCRP as human duodenal tissue. Gender specific differences in 
BCRP expression were not observed. These findings represent the first systematic site-specific 
analysis of BCRP expression along the GI tract. This information might be helpful to develop 
target strategies for orally administered anticancer drugs. 
 
 
3.2.2 Introduction  
BCRP/ABCG2 is a half-transporter that belongs to the white subfamily of ATP-binding cassette 
(ABC) transporters. BCRP was originally cloned from multidrug resistant tumour cells (Allikmets 
et al., 1998; Doyle et al., 1998; Miyake et al., 1999) and displays a wide substrate specificity. It 
mediates the energy dependent translocation of various anticancer drugs such as methotrexate 
(Volk et al., 2002), topoisomerase inhibitors (such as topotecan (Kruijtzer et al., 2002)), 
mitoxantrone, and doxorubicin (Doyle et al., 1998) across cellular membranes. BCRP knock-out 
mice were found to be healthy and showed no major pathological alterations. When fed with a 
chlorophyll rich diet containing the chloprophyll degradation product, the phototoxic 
phenophorbide a, the BCRP knock-out mice developed phototoxic skin lesions (Jonker et al., 
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2000). Its localization indicates an important role in the protection of tissues against xenobiotics. 
BCRP expression was detected mainly in excretory organs e.g. in canalicular membranes of the 
liver, in epithelial cells of the small intestine, colon, kidney and lung, as well as in the blood-brain 
barrier and the placenta (Scheffer et al., 2000; Maliepaard et al., 2001). 
The expression of BCRP in epithelial cells of the intestine implies, that BCRP might be an 
important transporter limiting the absorption of orally administered anticancer drugs and 
ingested toxins (Maliepaard et al., 2001; Jonker et al., 2002; Pavek et al., 2005). Due to its 
broad substrate specificity, BCRP might influence the pharmacokinetics of many unrelated 
substances including anticancer drugs, HIV drugs, and endogenous compounds (van 
Herwaarden et al., 2003; Polli et al., 2004). Up to now, there is little knowledge about the 
expression pattern of BCRP along the human intestine. This information however might be 
helpful for the development of specific galenical targeting approaches, which may be utilized to 
improve intestinal absorption of anticancer drugs. Therefore, the expression of BCRP was 
investigated in the human intestine of 14 healthy subjects and its duodenal expression was 
compared with that of MDR1. In vitro screening of drug absorption is commonly done in human 
intestinal cell lines (such as Caco-2 (Hilgers et al., 1990; Pfrunder et al., 2003) and LS180 
(Thummel et al., 2001)). Therefore, it is of interest to compare the expression level of BCRP in 
these cell lines with the human duodenal BCRP mRNA expression. 
In addition, membrane transport differences of endogenous and xenobiotic compounds 
associated with sex have been reported previously for several transport proteins (Piquette-Miller 
et al., 1998; Salphati and Benet, 1998; Urakami et al., 1999; Urakami et al., 2000; Buist et al., 
2002; Kobayashi et al., 2002; Buist and Klaassen, 2004). Recently, sex associated differences 
for Bcrp, the BCRP analogue in rat and mice has been described by Tanaka et al (Tanaka et al., 
2005). They observed a higher expression of Bcrp mRNA of male rats in the kidney and of male 
mice in the liver compared to females. These sex differences were attributed to the suppressive 
effect of estradiol in rats and to the inductive effect of testosterone in mice, respectively. 
Intestinal expression of rat and mouse Bcrp seems not be influenced by sex. However data 
about intestinal rat and mouse Bcrp expression exhibited high interspecies differences and were 
restricted to duodenum, jejunum and ileum. We therefore wanted to determine, whether there 
are sex-related differences in human BCRP mRNA expression along the intestinal tract that 
might lead to pharmacokinetic variations in drug absorption. 
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3.2.3 Material and Methods 
Cell cultures 
Caco-2 cells (passage 42) and LS180 cell line (passage 36) were purchased from ATCC 
(Manassas, USA). Both cell lines were cultured in Dulbecco’s MEM with Glutamax-I, 
supplemented with 10% (v/v) fetal calf serum, 1% non essential amino acids, 1% sodium 
pyruvate, 50µg/ml gentamycin. All cultures were maintained in a humified 37°C incubator with a 
5% carbon dioxide in air atmosphere. 
 
Biopsies 
Intestinal biopsies were obtained from 14 healthy subjects (7 female, 7 male, age 43-75 years, 
average age 59.8 years, no medication), which served as a control group in a clinical study. This 
study systematically investigated the regional expression of different genes in patients with 
inflammatory bowel disease. The study protocol included specifically the investigation of drug 
transporting proteins and it was approved by the local Ethical Committee. Informed consent was 
obtained from subjects prior to inclusion. Indications for a combined gastroscopy and 
colonoscopy in these control patients were cancer screening, irritable bowel syndrome and 
unspecific abdominal pain. No macroscopically pathological findings were observed during 
endoscopies in these subjects. Three to four biopsies each were obtained from duodenum, 
terminal ileum, ascending colon, transverse colon, descending colon and sigmoid colon. 
 
Preparation of samples and Taqman assay see Chapter 2 
 
Statistical Analysis 
BCRP gene expression was compared between the different intestinal segments by analysis of 
variance. In the case of significant differences between intestinal segments, all segments were 
compared with the expression in duodenum using Dunnett’s t-test using sex as a covariate. 
Comparison of BCRP and/or MDR1 mRNA expression was performed by unpaired two-sided t-
test. The level of significance was P =0.05. All statistical comparisons were performed using 
SPSS for Windows software (version 12.0). 
 
3.2.4 Results  
The expression pattern of BCRP from the duodenum to the sigmoid colon is shown in Figure 1. 
Maximal BCRP mRNA expression was found in the duodenum. In the colonic segments BCRP 
mRNA expression is continuously decreasing from proximal to distal. In ascending colon the 
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BCRP level is significantly reduced to 75.8 percent of the duodenum, in transverse colon to 66.6 
percent, in descending colon to 62.8 percent, and in sigmoid colon to 50.1 percent, respectively. 
In the terminal ileum BCRP mRNA expression is slightly but not significantly reduced compared 
to duodenum (93.7 percent). The expression of BCRP mRNA was not significantly different 
between males and females, neither in the duodenum and the terminal ileum, nor in the different 
colonic segments of the human GI tract (Figure 1). BCRP mRNA expression was normalized to 
villin to account for variation in enterocyte content (ratio of BCRP/villin mRNA) as suggested in 
the literature (Lown et al., 1997; Taipalensuu et al., 2001). This was justified, since the mRNA 
expression of villin was not significantly different between the different parts of the intestine. The 
variability of BCRP mRNA measurement was determined by repetitive determination (N = 10) 
and amounted to 4.3 % (coefficient of variation).  
 
Figure 1: Expression of BCRP/ABCG2 mRNA in different gut segments. Data represent means (± SEM) 
of biopsies from 14 healthy subjects (7 males, 7 females), except terminal ileum, where biopsies from 13 
subjects (6 males, 7 females) were used. 
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Since MDR1 and BCRP share some of their substrates, duodenal mRNA expression of these 
genes was compared. MDR1 mRNA and BCRP mRNA expression was in the same range in the 
duodenum, with a slightly but significantly (p<0.05) lower expression of BCRP (Figure 2). 
 
 
Figure 2: Expression of BCRP/ABCG2 mRNA and MDR1/ABCB1 mRNA in human duodenum normalized 
to the expression of villin. Data represent means (± SEM) of biopsies from 14 healthy subjects. 
 
The duodenal mRNA expression of BRCP was comparable to the expression in Caco-2 cells, 
which are reported to exhibit duodenal-like transporter expression (Pfrunder et al., 2003). 
However, the mRNA expression of BCRP in LS180 cells was almost 100-fold lower (p < 0.001; 
Figure 3). 
 
3.2.5 Discussion 
Previous studies had reported, that cellular BCRP is localized in the apical membranes of small 
intestinal and colonic epithelia (Maliepaard et al., 2001; Pavek et al., 2005), where it limits the 
bioavailability of toxic compounds. There is some information about tissue distribution of BCRP 
in animal species such as rat and mice or BCRP expression in isolated parts of the intestine 
(Taipalensuu et al., 2001; Tanaka et al., 2005). However, only limited information is available 
about the site-specific localization of BCRP along the GI tract in humans, which might be 
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important for the development of specific galenic formulations of anticancer drugs. Here, we 
present for the first time a systematic analysis of the site-specific expression of BCRP along the 
GI tract. BCRP mRNA expression decreased continuously from the duodenum to the sigmoid 
colon. In human jejunum, a part which was not investigated in our study due to ethical reasons, 
Taipalensuu et al. (Taipalensuu et al., 2001) found a high level of BCRP mRNA expression. The 
BCRP gene expression exhibited even a 3.4-fold higher expression than the MDR1 gene. Data 
in rat (Tanaka et al., 2005) have shown that the level of Bcrp gene expression is higher in the 
jejunum compared to duodenum. However, it is not trivial to extrapolate animal data to humans, 
because species differences have been described even between rodents. Whereas rats 
expressed high levels of Bcrp in the ileum, the ileal level of Bcrp mRNA in mice was rather low. 
Nevertheless one is tempted to speculate, that BCRP expression levels might be maximal in the 
jejunum. Since expression of BCRP is still high in the terminal ileum, which is close to the 
jejunum, these data are not in contrast to our findings. 
 
 
Figure 3: Expression of BCRP/ABCG2 mRNA in human duodenum (N=14); Caco-2 cells (N=3) 
and LS180 cells (N=3) normalized to the expression of villin. BCRP mRNA expression 
was significantly lower in LS180 cells than in Caco-2 cells and duodenal tissue (P < 
0.001). Data represent means (± SEM). 
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Differences in the membrane transport of xenobiotics and endogenous compounds caused by 
different levels of sexual hormones such as testosterone and estradiol have been previously 
described in several studies (Lu et al., 1996; Cerrutti et al., 2002). This sex related differences in 
membrane transport includes several membrane transporters such as organic cation 
transporters (Urakami et al., 1999; Urakami et al., 2000), organic anion transporters (Buist et al., 
2002; Kobayashi et al., 2002; Buist and Klaassen, 2004), and multidrug resistance proteins 
Mdr1a, Mdr1b and Mdr2 (Piquette-Miller et al., 1998; Salphati and Benet, 1998). Recently, 
Tanaka et al. reported sex-related differences of BCRP expression levels in rodents (Tanaka et 
al., 2005). We found no significant differences in the level of BCRP mRNA expression between 
males and females, neither in the duodenum and the terminal ileum, nor in the different colonic 
segments of the human GI tract. We therefore conclude, that sexual hormones have most 
probably no effect on the expression pattern of BCRP in the adult human intestine. The 
importance of MDR1 and MRPs for the protection from enteral absorption of potentially toxic 
xenobiotics and their limiting effects on enteral drug absorption has become more and more 
aware. BCRP shows some degree of substrate overlapping with these transporters and is also 
expressed in the small and large intestine (Allen and Schinkel, 2002). To estimate the potential 
impact of BCRP for detoxification and drug absorption, we compared the level of BCRP mRNA 
expression in the duodenum with the level of MDR1 mRNA, another important ABC-transporter 
of xenobiotics in the intestine. We showed comparable mRNA expression of MDR1 and BCRP, 
with a slightly but significantly (p<0.05) lower expression of BCRP. In jejunum, BCRP mRNA 
expression was found to be even higher as MDR1 mRNA expression (Taipalensuu et al., 2001). 
Taken together these findings indicate that BCRP might play an important role for limiting the 
absorption of orally administered anticancer drugs and ingested toxins. 
The comparable mRNA expression of BRCP in human duodenum and the colonic carcinoma 
derived cell line Caco-2 may indicate its usefulness for in vitro studies of BRCP mediated 
transport of drugs. In addition, another colonic adenocarcinoma-derived cell line, LS180, was 
investigated for BCRP mRNA expression. This cell line is commonly used for the assessment of 
gene induction (Thummel et al., 2001; Pfrunder et al., 2003; Collett et al., 2004). However, due 
to their low expression of BRCP mRNA, LS180 cells do not seem to be suitable for investigation 
of BRCP function. 
We have to admit that our study results represent only mRNA expression, which may not 
correlate with protein expression and/or function. However, due to ethical reasons we were 
limited with the number and volumes of tissue biopsies taken from our patients. Therefore, for 
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this mapping study only mRNA expression experiments could be performed. To assess 
functional expression of BRCP in different gut segments, further dedicated studies are needed. 
 
3.2.6 Conclusion 
These findings represent the first systematic site-specific analysis of BCRP expression along the 
GI tract and shows that its expression significantly decreased in all colonic segments compared 
with the small intestine. This knowledge might be important to develop target strategies for orally 
administered anticancer drugs. 
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3.3.1 Abstract 
Objective: Human breast cancer resistance protein (BCRP/ABCG2) is present on the apical 
membranes of the liver, in the epithelial cells of the small and large intestine and in kidney cells; 
the transporter mediates energy dependent efflux of drugs and potentially toxic compounds, and 
of various endogenous substrates such as bile acids. During obstructive cholestasis with a 
disrupted enterohepatic circulation, an adaptive regulation of several transporters for bile acids, 
bilirubin and cholesterol has been documented. An adaptive regulation of human intestinal 
BCRP during obstructive cholestasis has, however, not been described before.  
 
Methods: BCRP mRNA was quantified by real time PCR (Taqman) in duodenal biopsies of 14 
control subjects and compared to the duodenal BCRP mRNA expression of 19 patients with 
obstructive cholestasis. In addition, duodenal BCRP mRNA expression was measured in 4 
patients with obstructive cholestasis after reconstitution of bile flow. BCRP protein levels were 
determined in 6 cholestatic and 6 healthy subjects by immunohistochemistry. Finally, fasting bile 
acid and bilirubin concentrations were determined by specific assay systems. 
 
Results: Normalized duodenal BCRP mRNA expression (mean BCRP/Villin ± SEM) was 0.51 (± 
0.03) in controls and 0.27 (± 0.02) in cholestatic patients (p<0.001). In a semiquantitative 
analysis of immunohistochemical protein assessment (0 = no expression, 1 = low, 2 = 
intermediate, 3 = high expression) mean BCRP protein expression (mean±SEM) were 
significantly reduced in 6 patients with obstructive cholestasis (1.67 ± 0.38) when compared to 6 
healthy subjects 2.91 (± 0.08) (p< 0.005). After reconstitution of bile flow bile acid and bilirubin 
plasma levels returned to normal and BCRP mRNA expression increased  by 1.44-, 1.71-, 1.05-, 
and 1.90-fold, respectively (N=4).  
 
Conclusion: BCRP is down-regulated in the human duodenum during obstructive cholestasis. 
We infer that a reduced intestinal BCRP expression during cholestasis influences the 
accumulation of bile acids, food-derived carcinogens and the pharmacokinetics of various drugs 
that are transported by BCRP. 
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3.3.2 Introduction 
The breast cancer resistance protein (BCRP/ABCG2) is a half-transporter that belongs to the G 
subfamily of ATP-binding cassette (ABC) transporters. Similar to P-glycoprotein, BCRP was 
detected and cloned from multi-drug resistant tumour cells (Doyle et al., 1998; Miyake et al., 
1999). Both efflux transporters are highly expressed in organs that play a protective role against 
toxic substances such as the intestine, the kidney, the liver, the blood brain barrier, and the 
placenta (Maliepaard et al., 2001). In human jejunum, BCRP is expressed in the apical 
membrane of enterocytes along with other efflux pumps MRP2 (multidrug resistance associated 
protein 2) and P-glycoprotein, the gene product of MDR1/ABCB1 (multidrug resistance protein 
1) (Taipalensuu et al., 2001). BCRP mediates the translocation of various drugs like 
methotrexate, mitoxantrone, anthracyclines, SN-38, and topotecan (Doyle et al., 1998; Schellens 
et al., 2000; Volk and Schneider, 2003). It has further an essential role in extruding metabolites 
such as glucuronide and sulfate conjugates formed in enterocytes into the intestinal lumen 
(Adachi et al., 2005). Moreover, BCRP protects the body from toxic constituents of food such as 
the carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and the chlorophyll-
derived phototoxin pheophorbide a (Jonker et al., 2002; van Herwaarden et al., 2003). In 
summary, its localization in the apical membrane of intestinal cells and its wide substrate 
specificity suggests that BCRP is an important transporter limiting the absorption of orally 
administered drugs and ingested toxins.  
Most members of the ABCG subfamily are involved in the translocation of endogenous 
compounds. ABCG1 is supposed to be a regulator of cholesterol and phospholipid transport 
(Klucken et al., 2000), whereas the heterodimeric proteins ABCG5 / ABCG8 promote biliary 
excretion and limit intestinal absorption of neutral sterols (Yu et al., 2002). BCRP can also 
transport endogenous substrates such as sulphated steroids (Imai et al., 2003; Suzuki et al., 
2003) and primary bile acids (Janvilisri et al., 2005). The precise physiological role of BCRP 
remains, however, to be defined. 
BCRP is capable of transporting bile acids. This fact may indicate that this transporter is 
involved in bile acid homeostasis. As an efflux pump, it could protect the enterocytes from 
potential toxic bile acid concentrations. During cholestasis, in which the enterohepatic circulation 
is disrupted, an adaptive regulation of transporters for bile acids, bilirubin and cholesterol occurs 
(Tanaka et al., 2002; Zollner et al., 2003; Denk et al., 2004; Kamisako and Ogawa, 2005). These 
changes take place in the liver, the kidney, as well as in the intestine. We have recently shown 
that the responsible gene for bile acid reuptake in the intestine, the apical sodium dependent bile 
acid transporter (ASBT), is down-regulated in cholestatic patients (Hruz et al., 2006). 
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Here we have analyzed the intestinal expression of BCRP in patients with obstructive 
cholestasis. The disease is associated with elevated bile acid levels in serum, a lack of bile 
acids in the intestinal lumen, and increase in proinflammatory cytokines (Plebani et al., 1999). 
We hypothesized that BCRP, as a potential bile acid transporter, could show an altered gene 
expression during obstructive cholestasis. Indeed, we can show that cholestatic patients exhibit 
decreased BCRP expression in the intestine compared to healthy subjects. Further studies are 
necessary to characterize the impact of these results on the pharmacokinetics of drugs that are 
BCRP substrates.  
 
3.3.3 Material and Methods 
Patients  
Fourteen healthy subjects (7 females, 7 males) and 19 cholestatic patients (10 females, 9 
males) were enrolled in the study after giving informed consent. The group of control subjects 
had a mean age of 59.8 years and cholestatic patients of 67.5 years, whereas bile acid levels 
were 1.7 (0.5 - 3.2) and 122.6 (20.5 - 431.3) µmol/L, respectively.  
 
Table 2: Biochemical Parameters (means ± SD) 
 
Parameter Control Patients with 
cholestasis 
P-Value 
Bilirubin  
(5-26 µmol/L) 
11.1 ± 2.9 235.1 ± 186.2 P < 0.001 
ALAT  
(10-37 U/L) 
24.2 ± 9.2 193.1 ± 163.1 P < 0.003 
ASAT  
(11-36 U/L) 
23.4 ± 7.9 122.1 ± 102.5 P < 0.002 
γ-GT  
(11-66 U/L) 
58.0 ± 7.6 578.3 ± 430.3 P < 0.001 
AP  
(43-106 U/L) 
65.5 ± 13.1 375.5 ± 416.5 P < 0.01 
Total cholesterol  
(3-5.2 mmol/L) 
5.5 ± 0.8 32.8 ± 101.1 NS 
Bile acids  
(< 10 µmol/L) 
1.7 ± 0.7 122.6 ± 108.8 P < 0.001 
Note. Normal range in parenthesis; NS = statistically not significant 
 
The control subjects had an indication for a gastrointestinal tract endoscopy within a cancer-
screening program, whereas patients with obstructive cholestasis had an interventional 
endoscopic retrograde cholangiopancreatography (ERCP). Within the cholestatic group, nine 
  75 
patients had obstructive tumors (3 carcinoma of the pancreatic head, 4 cholangiocarcinoma 
(Klatskin tumor) and 2 metastatic disease). 10 patients had benign diseases (8 patients with 
choledocholithiasis and two patients with a benign stenosis of the common bile duct). 
Obstructive jaundice was defined on the basis of chemical parameters (bilirubin, γ-
glutamyltransferase, and alkaline phosphatase) and on imaging procedures (ultrasound and 
ERCP) demonstrating a dilated bile duct system. All control patients had normal values of the 
above mentioned parameters. During endoscopy four biopsy specimens were obtained from the 
distal part of the duodenum. Biopsies were immediately stored at –70°C until further processing. 
The study was approved by the State Ethical Committee of Basel (Ethische Kommission beider 
Basel, EKBB). 
 
Real-time RT-PCR analysis (TaqMan) described in Chapter 2 
Sequences of PCR primers used for generating the standards and of TaqMan primers / probes 
used for real-time PCR (Table 2.1; Chapter 2) 
 
Immunohistochemical assessment is described in Chapter 2 
 
Determination of bile acid plasma concentrations is described inChapter 2 
 
Statistics 
All values were expressed as means ± SEM. Icteric patient’s BCRP expression was compared 
to that of healthy controls by analysis of variance (ANOVA). All comparisons were performed as 
two-sided comparisons using the SPSS for Windows software (version 12.0). Level of 
significance was p<0.05. 
 
 
3.3.4 Results 
3.3.4.1 BCRP mRNA expression is down-regulated during cholestasis 
Intestinal mRNA expression of BCRP and villin was analyzed in 14 healthy subjects and 19 
patients with obstructive cholestasis. In cholestatic patients mean BCRP mRNA levels were 
reduced to 53.6 % when compared to healthy subjects. Relative expression (mean BCRP/villin ± 
SEM) was 0.51 (± 0.03) in controls and 0.27 (± 0.02) in cholestatic patients (p<0.001) (Figure 
1A). Mean villin mRNA expression was not significantly different between the control and 
cholestatic group (data not shown).  
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Figure 1A and 1B: Comparison of BCRP expression in healthy subjects versus cholestatic patients 
(mean ± SEM). 1A: Expression of BCRP mRNA relative to villin (14 controls versus 19 cholestatic 
patients). 1B: BCRP protein expression using immunohistochemistry with semiquantitative analysis (6 
controls vs. 6 cholestatic patients). 
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Figure 2 displays the individual BCRP mRNA expression in correlation to bile acid serum 
concentration.  
 
 
 
Figure 2: Individual BCRP mRNA expression (BCRP/villin) in correlation to bile acid plasma concentration 
in healthy subjects and cholestatic patients.  
 
In 4 patients a follow-up gastroscopy could be performed after reconstitution of bile flow. These 
patients showed normalized bile acid and bilirubin plasma levels at the time when duodenal 
follow-up biopsies were taken. In all 4 patients the BCRP mRNA expression increased (1.44-, 
1.71-, 1.05-, and 1.90-fold) when compared to the expression level of cholestasis (Figure 3).  
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Figure 3:Change of relative BCRP mRNA expression (BCRP/villin) in 4 patients during cholestasis and 
after reconstitution of bile flow.  
 
3.3.4.2 BCRP protein levels are decreased in cholestatic patients  
BCRP protein expression was evaluated by immunohistochemistry. Semiquantitative analysis in 
biopsies of 6 control subjects and 6 cholestatic patients was done by a trained pathologist. 
BCRP protein was expressed on the apical membrane of the duodenal epithelial cells. 
Representative pictures of duodenal tissues are displayed in Figure 4A (healthy subject) and 4B 
(cholestatic patient). Expression levels were rated as follows: 0 = no expression, 1 = low, 2 = 
intermediate, 3 = high expression. In patients with obstructive cholestasis mean BCRP protein 
levels were reduced to 57.1 % when compared to healthy subjects. Protein expression (mean ± 
SEM) was 2.91 (± 0.08) in control subjects and 1.67 (± 0.38) in cholestatic patients (p< 0.005) 
(Figure 1B). 
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Figure 4A and 4B: Immunohistochemical localization of BCRP protein on the apical membrane of human 
duodenal epithelial cells using a polyclonal rabbit anti-human BCRP antibody (all pictures at 200-fold 
magnification). 4A: clear staining of BCRP protein in a duodenal sample from a healthy subject. 4B: 
reduced staining in a duodenal sample of a patient with obstructive cholestasis 
  
3.3.5 Discussion 
Our data demonstrate that during complete or near complete obstruction of the bile duct by a 
tumour or biliary stone cholestasis intestinal BCRP expression is down-regulated on the 
transcriptional level leading to reduced amount of BCRP protein. As a proof of principle, 
reconstitution of bile flow by endoscopic or surgical therapy initiated normalization of intestinal 
BCRP expression associated with normalization of serum bile acids and bilirubin levels. 
 
At the moment, little is known about the transcriptional regulation of this transporter. Only 
recently, an estrogen response element in the BCRP promotor was discovered (Ee et al., 2004). 
Tanaka and coworkers observed, however, a higher BCRP expression in the kidney and liver of 
male rats and male mice, respectively (Tanaka et al., 2005). Furthermore, it has been reported 
that estrogens down-regulate BCRP protein expression by posttranscriptional mechanisms (Imai 
et al., 2005). Recently we have analyzed BCRP mRNA expression along the human 
gastrointestinal tract of healthy subjects with respect to sex (Gutmann et al., 2005). No sex-
related differences were observed. The data of the present study again show no significant 
differences between women and men (data not shown). We infer from these data that sexual 
hormones have most probably no effect on the expression of BCRP in the human intestine. 
This is the first study demonstrating that the expression of BCRP is altered in the human 
intestine during disease. Our results are in conflict with another study, where no differences in 
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duodenal BCRP protein levels were observed between icteric patients and healthy subjects 
(Dietrich et al., 2004a). The authors analyzed the expression of several ABC-transporters 
including BCRP in the human intestine and found only MRP2 to be down-regulated. A possible 
explanation for this discrepancy could be different durations and/or severity of cholestasis 
between the two patient groups in both studies.   
During cholestasis, the expression of bile acid and bilirubin transporters such as the ABC-
transporters MRP2, MRP3, MRP4, and organic anion transporting polypeptides (OATPs) is 
significantly changed (Tanaka et al., 2002; Wagner et al., 2003; Denk et al., 2004; Dietrich et al., 
2004a). Alterations in transporter expression do not only occur in the liver but also in remote 
organs such as the kidney and intestine. The systemic mediators that regulate these events 
during cholestasis have not been fully discovered. Proinflammatory cytokines, bile salts, or 
hormones have been suggested to control transporter gene expression (Trauner et al., 2005).  
 
IL-1 β has been identified as the central mediator for the down-regulation of intestinal MRP2 
(Denson et al., 2002; Dietrich et al., 2004a). In liver, TNF-α and IL-1 β are responsible for the 
down-regulation of several hepatobiliary transporters (Geier et al., 2003). Cytokines mediate 
these effects by reducing the binding activity of nuclear receptors to the corresponding 
promoters (Denson et al., 2002; Geier et al., 2003; Li and Klaassen, 2004). Bile acids act 
through binding to their endogenous receptor farnesoid X receptor (FXR), which induces the 
expression of small heterodimer partner (SHP) (Lu et al., 2000). SHP in turn represses the 
expression of several genes involved in bile acid homeostasis (Jung and Kullak-Ublick, 2003; 
Popowski et al., 2005). PXR is a further transcription factor that can be activated by bile acids 
(Xie et al., 2001). PXR activation leads to the induction of multiple detoxification pathways 
including transporters (Stedman et al., 2005). Moreover, hormones like glucocorticoids can 
influence transporter expression, as they are able to transactivate the intestinal bile acid 
transporter ASBT via the glucocorticoid receptor (Jung et al., 2004). However, until now, there 
are no indications that intestinal BCRP is also regulated by these mechanisms. Members of the 
ABCG subfamily such as ABCG1 and ABCG5 / ABCG8 are repressed by bile acids via the FXR-
SHP pathway in vitro (Brendel et al., 2002; Freeman et al., 2004). This demonstrates that further 
investigations of BCRP regulation are required.  
In the state of obstructive cholestasis virtually no bile acids are present in the intestinal lumen. If 
BCRP mediates the efflux of bile salts that enter the enterocyte from the lumen, a down-
regulation of this transporter would make sense. On the other hand, as BCRP is a potent efflux 
pump for a variety toxic compounds, a diminished expression could weaken the intestinal barrier 
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and the excretory function of the gut. Dietrich and coworkers determined the elimination of the 
dietary carcinogen PhIP in bile duct ligated rats (Dietrich et al., 2004b). They demonstrated that 
the excretion of this toxin was significantly reduced in parallel with a decreased expression of 
MRP2 and BCRP in liver. Furthermore, tissue binding of reactive metabolites was increased in 
liver and colon. A reduced intestinal BCRP expression could substantially contribute to the 
accumulation of carcinogens in the gut enterocytes. This might partly explain the observation 
that patients with primary sclerosing cholangitis, a chronic cholestatic disease, have a higher risk 
of developing colorectal carcinoma (Broome et al., 1995). 
In conclusion, we showed that patients with obstructive cholestasis exhibit a decreased 
expression of BCRP on mRNA and protein level. After reconstitution of bile flow BCRP mRNA 
levels normalized in all follow-up patients. Therefore, mediators that are associated with 
cholestasis seem to influence BCRP expression on the transcriptional level. Importantly, a 
decreased expression of this efflux pump could increase the accumulation of food-derived 
carcinogens and influence the pharmacokinetics of various anticancer drugs. Whether these 
results have clinical implications for cancer therapy is beyond the scope of this study. 
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3.4.1 Abstract 
Efflux transporters such as P-glycoprotein and multidrug resistance-associated proteins (MRPs) 
in the intestinal wall restrict intestinal drug transport. To overcome this limitation for enteral drug 
absorption, galenical targeting approaches have been proposed for site-specific luminal drug 
release in segments of the gut, where expression of the respective absorption-limiting 
transporter is minimal. Therefore, expression of multidrug resistance gene 1 (MDR1) and MRP1-
5 was systematically investigated in 10 healthy subjects. Biopsies were taken from different 
segments of the gastrointestinal tract (from duodenum, terminal ileum as well as ascending, 
transverse, descending, and sigmoid colon). Gene expression was investigated by quantitative 
real-time PCR (TaqMan). MRP3 appeared to be the most abundantly expressed transporter in 
the investigated parts of the human intestine, except for the terminal ileum, where MDR1 
showed the highest expression. The ranking of transporter gene expression in the duodenum 
was MRP3>>MDR1>MRP2>MRP5>MRP4>MRP1. In the terminal ileum the ranking order was 
as follows: MDR1>MRP3>>MRP1≈MRP5≈MRP4>MRP2. In all segments of the colon 
(ascending, transverse, descending, and sigmoid colon), the transporter gene expression 
showed the following order: MRP3>>MDR1> MRP4≈MRP5>MRP1>>MRP2. We have shown, 
for the first time, systematic site-specific expression of MDR1 and MRPs along the 
gastrointestinal tract in humans. All transporters showed alterations in their expression levels 
from the duodenum to sigmoid colon. The most pronounced changes were observed for MRP2 
with high levels in the small intestine and hardly any expression in colonic segments. This 
knowledge may be useful to develop new targeting strategies for enteral drug delivery. 
 
3.4.2 Introduction  
Efflux transporters in the intestinal wall form a barrier to cellular accumulation of toxins as well 
as to drug absorption (Schinkel, 1997). Important efflux proteins in the gut are P-glycoprotein 
[gene product of the multidrug resistance 1 (MDR1) gene] and multidrug resistance-associated 
protein (MRP) transporters. They belong to the superfamily of ATP-binding cassette (ABC) 
transporters. ABC transporters mediate the translocation of a wide variety of substances across 
cellular membranes using ATP hydrolysis (Horio et al., 1991; Senior et al., 1995). The 
expression of ABC transporter genes is widespread throughout many tissues, most notably in 
excretory sites such as the liver, kidney, blood-brain barrier, and intestine. Therefore, they play a 
critical role in absorption and tissue distribution of orally administered drugs (Schuetz et al., 
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1998; Ambudkar et al., 1999). Due to their broad substrate specificity, they may influence the 
pharmacokinetics of many chemically unrelated substances (e.g., HIV drugs, anticancer drugs, 
endogenous compounds) (Lee et al., 1997; Schinkel, 1998; Schuetz et al., 1999; Borst et al., 
2000). MDR1 preferentially extrudes large hydrophobic, positively charged molecules, whereas 
the members of the MRP family extrude both hydrophobic uncharged molecules and water-
soluble anionic compounds.  
There is little knowledge about the expression pattern of those ABC transporters along the 
human intestine. Taipalensuu investigated gene expression of 10 ABC transporters in jejunal 
biopsies from healthy subjects (Taipalensuu et al., 2001). The highest expression was shown for 
breast cancer resistance protein and MRP2. Nakamura investigated the expression of three 
ABC transporters in duodenal and colorectal tissues in humans (Nakamura et al., 2002). In 
comparison to duodenum, in colon they found a decrease in MDR1 expression, equal levels of 
MRP1, and a strong decrease in MRP2 expression. However, this comparison was not obtained 
in the same subjects. Therefore, the intraindividual expression differences between these 
transporters could not be assessed. 
Knowledge of the topographical distribution may be important for the development of specific 
galenical targeting approaches, which may be utilized to improve intestinal absorption of drugs. 
Therefore, in this study, the expression of MDR1 and MRP1-5 genes was investigated in the 
human intestine of 10 healthy subjects. 
   
 
3.4.3 Material and methods 
Intestinal biopsies 
Intestinal biopsies were obtained from a group of 10 healthy subjects (5 female, 5 male, aged 
50–76 years, average age 62 years, no medication), which served as a control group in a clinical 
study designed to investigate the regional expression of different genes in patients with 
inflammatory bowel disease. The study protocol included specifically the investigation of 
drugtransporting proteins and was approved by the local ethical committee (Ethische 
Kommission beider Basel, EKBB). Informed consent was obtained from all subjects prior to 
inclusion. No macroscopically pathological findings were observed during endoscopies in these 
subjects. Three to four biopsies were obtained from duodenum, terminal ileum, ascending colon, 
transverse colon, descending colon, and sigmoid colon (Figure 3.4.1). Due to low enterocyte 
content, duodenal biopsies from one subject had to be discarded, leading to nine duodenal 
samples. 
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Figure 3.4.1 Schematic overview of biopsy sampling. Samples were taken from the duodenum (A), 
terminal ileum (B), ascending colon (C), transverse colon (D), descending colon (E), and sigmoid colon 
(F). 
 
 
Preparation of Samples and Taqman analysis was described in chapter 2 
 
Statistical analysis 
Gene expression was compared between the different intestinal segments by analysis of 
variance. In the case of significant differences, all segments were compared with the expression 
in duodenum using two-sided Dunnett’s multicomparison t test. The level of significance was 
P<0.05. Comparisons were performed using SPSS for Windows software (version 11.0; SPSS 
Inc., Chicago, IL). 
 
3.4.4 Results 
There was a considerable interindividual variability of transporter gene expression amounting on 
average to 34% (CV%). Figure 3.4.2 displays the expression and ranking of all transporters in 
the analyzed tissues normalized to villin. MRP3 appeared to be the most abundantly expressed 
transporter in the investigated parts of the human intestine, except for the terminal ileum where 
MDR1 showed the highest expression. The ranking of transporter gene expression in the 
duodenum was MRP3 >> MDR1 > MRP2 > MRP5 > MRP4 > MRP1. In the terminal ileum the 
  88 
ranking order was as follows: MDR1 > MRP3 >> MRP1 ≈ MRP5 ≈ MRP4 > MRP2. In all 
segments of the colon (ascending, transverse, descending, and sigmoid colon), the transporter 
expression showed the following order: MRP3 >> MDR1 > MRP4 ≈ MRP5 > MRP1 >> MRP2. 
 
 
Figure 3.4.2: Expression of all investigated transporters in the analyzed tissues normalized to villin 
expression. Data represent means (± SEM) of biopsies from 10 health subjects, except duodenum, where 
biopsies from 9 subjects were used. 
 
Figure 3.4.3 shows the expression pattern of each individual transporter from the duodenum to 
the sigmoid colon normalized to villin. Compared with the duodenum, the expression of MDR1 
was 4- fold higher in the terminal ileum and approximately 2-fold higher in the colonic segments. 
MRP1 exhibited a 2- to 3-fold higher expression in both the terminal ileum and colon compared 
with duodenum. MRP2 showed highest expression in the duodenum, half-levels in the terminal 
ileum, and hardly any MRP2 transcripts in each colonic segment. MRP3, MRP4, and MRP5 
exhibited a similar expression pattern with equal levels in the duodenum and terminal ileum, but 
a 2- to 3-fold increase in the colon. Within the colon, MRP1, MRP3, and MRP5 showed an 
expression pattern with decreasing levels from proximal to distal, whereas MDR1, MRP2, and 
MRP4 levels remained rather constant. 
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Figure 3.4.3 (A – F): Transporter specific gene expression in different gut segments normalized to the 
villin expression. A: MDR1, B: MRP1, C: MRP2, D: MRP3 E: MRP4 and F: MRP5. Data represent means 
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(± SEM) of biopsies from 10 healthy subjects, except duodenum, where biopsies from 9 subjects were 
used. 
 
3.4.5 Discussion 
Only little information is available about the expression of ABC transporters along the intestinal 
tract. Available information relates mainly to MDR1 and MRP2 expression (Dietrich et al., 2003; 
Lindell et al., 2003) and previous studies have usually focused on isolated parts of the intestine 
(Taipalensuu et al., 2001; Lindell et al., 2003), on animal models (Achira et al., 2002; Takara et 
al., 2003), or on cancer cells (Nakamura et al., 2002; Li et al., 2003; Pfrunder et al., 2003). In the 
present study, systematic site-specific expression of MDR1 and MRP isoforms along the 
gastrointestinal tract in humans was shown. All transporters showed alterations in their 
expression levels from the duodenum to the sigmoid colon. The most pronounced changes were 
observed for MRP2, with high levels in the small intestine and hardly any expression in colonic 
segments. One drawback of the present study is the lack of samples from the jejunum, an 
important site for drug absorption. Because the subjects in our study underwent combined 
gastroscopy and colonoscopy procedures for screening of gastrointestinal cancer, jejunoscopy 
was not indicated and could not be performed. However, Taipalensuu and co-workers focused 
on the human jejunum and found a transporter expression with the following ranking: MRP2 > 
MDR1 ≈ MRP3 > MRP5 ≈ MRP1 > MRP4 (Taipalensuu et al., 2001). This transporter 
expression pattern in the jejunum, besides the high MRP2 levels, shows strong similarity to the 
pattern we found in the terminal ileum, which is conclusive because of the proximity of these 
tissues.  
It is suggested that MDR1 physiologically functions as a gatekeeper against xenobiotics in the 
gut. The bioavailability of many drugs is reduced due to MDR1 efflux. MDR1 shows extremely 
broad substrate specificity, including anticancer agents, antibiotics, antivirals, calcium channel 
blockers, and immunosuppressants. With respect to the expression of MDR1 in the human 
intestine, an increase from proximal to distal was stated, with the highest expression levels 
documented in the colon (Fricker et al., 1996; Dietrich et al., 2003; Chan et al., 2004). In mice, 
however, Chianale and co-workers found the highest levels of mdr3 mRNA in the ileum 
(Chianale et al., 1995). In the rat intestine, the P-glycoprotein-mediated drug efflux showed 
highest activity in the ileum as well (Stephens et al., 2001). We could also demonstrate, in 
humans, higher MDR1 mRNA levels in the terminal ileum compared with the duodenum. These 
results are consistent with human data from Mouly and Pain, who reported an increase in P-
glycoprotein from duodenum to ileum (Mouly and Paine, 2003). 
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MRP1 showed the lowest variation in mRNA levels within the intestinal tract. This is in good 
agreement with the fact that MRP1 is expressed ubiquitously. Physiologically important 
substrates for MRP1 include glutathione S-conjugates such as leukotriene C4, as well as 
bilirubin glucuronides (Keppler et al., 1998). In addition, anionic drugs and drugs conjugated to 
glutathione, like methotrexate or arsenite, are also transported by MRP1 (Bakos et al., 2000; 
Vernhet et al., 2000). 
Relatively low MRP2 mRNA levels were found in the human duodenum and even lower levels in 
the terminal ileum, but almost no MRP2 expression in the entire colon. These results were also 
found in the rat intestine (Mottino et al., 2000; Rost et al., 2002), but up to now, they were not 
confirmed in humans. Our results are also consistent with the expression pattern of glutathione 
S-transferase in the human gastrointestinal tract mucosa (Coles et al., 2002). This phase II 
metabolizing enzyme provides the conjugated compounds for subsequent export by MRP2 or 
MRP1. The substrate specificity of MRP2 is similar to that of MRP1, and includes glutathione 
conjugates, bilirubin glucuronides, and a number of drugs and their conjugated drug metabolites 
(Jedlitschky et al., 1997; Kawabe et al., 1999), including pravastatin, temocaprilat, irinotecan, 
SN-38, arsenite, cisplatin, methotrexate, vincristine, saquinavir, and ceftriaxone (Kusuhara and 
Sugiyama, 2002; Dietrich et al., 2003). Regarding the amount of drugs transported by MRP2, a 
drug targeting which circumvents absorption sites with high MRP2 expression would be of 
benefit, especially for drugs with low bioavailability. MRP3 transports a wide range of bile salts 
and seems to be involved in their reabsorption (Hirohashi et al., 2000). For MRP3, Rost and 
coworkers showed low expression in the rat duodenum and high expression in the ileum and 
colon (Rost et al., 2002). Here, low MRP3 expression in the duodenum as well as in the terminal 
ileum was shown. MRP3 expression increased in the colon but diminished slightly from proximal 
to distal segments. This reduction in transporter expression from ascending to sigmoid colon 
was observed for MRP1, MRP3, and MRP5. Interestingly, all of these transporters are located 
on the basolateral membrane. For MDR1, MRP2, and MRP4, probably located on the apical 
membrane (Chan et al., 2004) we observed rather constant expression levels throughout the 
entire colon. 
With respect to MRP4, we found equal expression levels in the duodenum and the terminal 
ileum but a 3-fold increase in the colon. To our knowledge, there is no previous publication on 
the MRP4 expression in the colon. However, in lymphoblastoid cell line lines an overexpression 
of MRP4 severely impaired the antiviral efficacy of adefovir, azidothymidine, and other 
nucleoside analogs (Schuetz et al., 1999). Other substrates include folic acid, bile acids, 
methotrexate, and 6-mercaptopurine (Wielinga et al., 2002; Chan et al., 2004). A physiological 
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role of MRP4 might be the release of prostaglandins from cells (Reid et al., 2003). Similarly, 
MRP5 showed low expression in the small intestine, but a 2-fold increase in the different colon 
segments. Both, MRP4 and MRP5 have an affinity to nucleotide-based substrates. There are no 
reports, at present, which could suggest a role for MRP5 in intestinal drug disposition. 
Experiments with transfected cells showed enhanced efflux of 2,4-dinitrophenyl-S-glutathione, 
adefovir, and the purine analogs 6-mercaptopurine and thioguanine (Wijnholds et al., 2000). 
Jedlitschky and co-workers demonstrated that MRP5 transports the cyclic nucleotides cAMP 
and cGMP (Jedlitschky et al., 2000), but the physiological function of this transporter remains to 
be elucidated.  
 
3.4.6 Conclusion 
In this study, for the first time, systematic site-specific expression of MDR1 and MRP isoforms 
along the gastrointestinal tract in humans was shown. All transporters showed alterations in their 
expression levels from the duodenum to the sigmoid colon. The most pronounced changes were 
observed for MRP2, with high levels in the small intestine and hardly any expression in colonic 
segments. The knowledge of transporter expression along the intestinal tract may be useful to 
develop new targeting strategies for enteral drug delivery. 
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4.1 Abstract 
Introduction: Multidrug resistance transporters such as MDR1, MRP1-5 and BCRP are 
membrane efflux pumps that extrude a wide variety of drugs and endogenous compounds, 
thereby reducing their intracellular concentration. Therapy resistance in patients with an acute or 
chronic inflammatory disease treated with drugs which are substrates of MDR transporters is a 
relevant clinical problem. As macrophages play an important role in innate immune response, 
the knowledge of the transporter expression in the monocyte and in the monocyte derived 
macrophage might be of special value for pharmacological treatment and could be essential for 
understanding treatment failure in patients with acute or chronic inflammatory disease. 
Methods: Peripheral blood mononuclear cells (PBMC`s) were isolated from venous blood of 5 
healthy donors. The CD14+ PBMC subpopulation (monocytes) was purified by magnetic cell 
separation and cultivated in AB-serum containing medium for 7 days, to obtain monocyte 
derived macrophages (MDM). On day 6 part of the differentiated cells were stimulated with 
lipopolysaccharide (LPS) for 24h. Cells were phenotyped by staining with FITC-conjugated 
mouse monoclonal antibodies (mAb) to human HLA-DR, CD14, CD71 and CD 206.  MDR1, 
MRP1-5 and BCRP mRNA expression was measured by real time PCR (Taqman). 
Results: MDR1 and BCRP mRNA was not expressed in monocytes and only low expression 
was found in MDM for both transporters, which decreased insignificantly after incubation with 
LPS. MRP1 mRNA expression was lowest in monocytes and increased significantly with 
differentiation into MDM (p < 0.01) as well as after stimulation with LPS (p < 0.001). In contrast, 
highest MRP2 mRNA expression was found in monocytes, which decreased by six fold after 
differentiation into MDM (p < 0.001). MRP3-5 showed a similar expression pattern with the 
lowest gene expression in monocytes, which increased significantly during differentiation into 
MDM and decreased after LPS stimulation. 
Conclusion: The investigated ABC transporters MDR1, MRP1-5 and BCRP showed different 
gene expression patterns during differentiation of monocytes into MDM and subsequent 
stimulation with LPS, indicating different physiological functions. 
 
4.2 Introduction 
ATP- binding cassette (ABC) transporters are transmembrane proteins that translocate a wide 
variety of substrates across extra- and intracellular membranes using ATP hydrolysis (Horio et 
al., 1988). Multidrug resistance transporter 1 (MDR1; ABCB1), multidrug  resistance associated 
protein 1-5 (MRP1-5; ABCC1-5), as well as the breast cancer resistance protein (BCRP; 
ABCG2) are membrane efflux pumps which form a barrier to cellular accumulation of toxins as 
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well as to drug absorption, thereby lowering their intracellular concentration (Schinkel, 1997) and 
protecting tissue from xenobiotic accumulation and subsequent toxicity. Multidrug resistance is a 
phenomenon in which a cell exposed to a single drug, becomes cross-resistant to a large 
number of structurally unrelated compounds. Expression of P-glycoprotein (P-gp; gene product 
of the MDR1 gene) in different types of solid tumors and in leukemias has been associated with 
clinical resistance to chemotherapy, indicating that P-gp mediated multidrug resistance is an 
important clinical problem (Plaat et al., 2000; Sonneveld, 2000). Furthermore, there is increasing 
evidence that several multidrug resistance transporter play an important role in acute and 
chronic inflammatory processes (Wijnholds et al., 1997; Panwala et al., 1998) and might 
contribute to the development of therapy resistance in certain inflammatory diseases (Maillefert 
et al., 1996; Farrell et al., 2000). Spontaneous intestinal inflammation similar to that of human 
IBD was observed in mdr1a (-/-) mice (Panwala et al., 1998). Patients with UC and CD exhibited 
decreased Pgp expression in CD3+ intestinal lymphocytes when compared to healthy controls 
(Yacyshyn et al., 1999). High MDR1 protein expression in CD3+ circulating lymphocytes in IBD 
patients that required surgery several years earlier for failed medical therapy was demonstrated 
(Farrell et al., 2000) and a significant correlation between peripheral blood lymphocytes and 
colonic mucosal MDR expression among patients with IBD and controls was found. These 
results implicate that MDR expression might play a role in determining the response of IBD 
patients to therapy.  
In IBD, besides lymphocytes, other cell types such as macrophages play a key role in 
orchestrating a specific mucosal immune response. Peripheral blood monocytes, which originate 
from bone marrow progenitor cells, mature to different types of histiocytes and macrophages 
when they migrate from the bloodstream into various tissue. Macrophages have been shown to 
express an activated phenotype (CD14+) in patients with IBD that is usually not expressed in 
normal intestine (Rogler et al., 1997). These activated macrophages can substantially enhance 
the immune response in patients with IBD by acting as an antigen presenting cell (APC) and by 
secreting proinflammatory cytokines such as IL-1, IL-6, IL-12, IL-18 and TNFα.  
Several drugs used in the treatment of IBD patients are MDR, MRP or BCRP substrates. In vitro 
models with high MDR or MRP overexpressing cells have provided experimental evidence, that 
glucocorticoids (Pgp, MRP4), sulfasalazine (BCRP), cyclosporine (Pgp), methotrexate (MRP1-3) 
and the active metabolite of the inactive prodrug azathioprine, 6-mercaptopurine (MRP5) are 
actively transported out of these cells (Ueda et al., 1992; Schinkel et al., 1995; Borst et al., 1999; 
Borst et al., 2000; Keppler et al., 2000; van der Heijden et al., 2004). 
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Although, MDR1, MRP1-5 and BCRP are expressed in a variety of normal tissues very little is 
known about their expression and function in cells of the immune system. Therefore, MDR1, 
MRP1-5 and BCRP mRNA expression was investigated in human peripheral blood monocytes 
and monocyte derived macrophages (MDM). In addition, the effect of lipopolysaccharide (LPS) 
incubation on MDM on the gene expression of MDR transporters was studied. Knowledge of 
MDR transporter expression in the monocyte and in the monocyte derived macrophage might 
contribute to the improvement of pharmacological treatment of IBD patients and might help to 
understand better the molecular mechanisms leading to treatment failure in patients with 
inflammatory diseases. 
 
4.3 Material and Methods 
4.3.1 Reagents 
All chemicals were of highest quality available and were obtained from commercial sources. LPS 
preparation (Salmonella enterica serovar typhimurium) was purchased from Sigma Chemical Co 
(St. Louis, Mo.). 
 
4.3.2 Preparation and culture of peripheral blood monocytes 
Peripheral blood mononuclear cells (PBMC`s) were isolated from venous blood of 5 healthy 
donors (5 male, average age 34.2 years, no medication) by Ficoll gradient centrifugation. CD14+ 
PBMC subpopulation (monocytes) was purified by magnetic cell separation (Miltenyi Biotech, 
Bergisch Gladbach, Germany) using CD14+ magnetic beads according to producer`s protocol. 
Monocytes then were cultured at 37°C in RPMI medium  supplemented with gentamycin 15 
µg/ml, sodium pyruvate (0.5 mM), hepes (0.75 mM), glutamax (1mM), non essential amino acids 
(all from Gibco Paisley, Scotland), 5% fetal calf serum and 10% heat inactivated (30 min at 
56°C, which does not destroy LBP bioactivity) human serum (pool of six samples from healthy 
individuals with blood group AB from the blood donor bank, Blutspendezentrum, 
Universitätsspital Basel, Switzerland). Cultivation was performed in hydrophobic quadriPERM 
Teflon wells (Vivascience, Göttingen, Germany) for 7 days with or without stimulation with LPS 
100 ng/ml culture medium after 6 days (intermediate feeding of medium). 
 
4.3.3 Phenotyping of cells 
Cells were phenotyped by staining with FITC-conjugated mouse monoclonal antibodies (mAb) to 
human HLA-DR, CD14, CD71 and CD206 (Becton Dickinson, San Diego, USA). Cell acquisition 
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was done by a flow-cytometer (FACScalibur) equipped with Cell Quest software (Becton 
Dickinson, San Diego, USA). 
 
Real time polymerase chain reaction analysis of human MDR1, MRP1-5, BCRP mRNA 
(TaqMan assay) as described in Chapter 2 
 
Statistical analysis 
Gene expression was studied in CD14+ PBMC`s (monocytes), monocyte derived macrophages 
with and without stimulation with LPS. For the comparison of the gene expression level the 
Tukey test was used. The level of significance was P <0.05. Comparisons were performed using 
SPSS for windows software (version 12.0, SPSS Inc., Chicago, USA). 
 
4.4 Results 
For the analysis of ABC transporter mRNA of CD14+ PBMC`s (monocytes) during differentiation 
into monocyte derived macrophages (MDM) and subsequent activation with LPS, isolated 
monocytes from peripheral blood of healthy donors were cultured in human AB-serum 
containing medium. One part of the cultured cells was used for phenotyping by staining with 
FITC-conjugated mouse monoclonal antibodies (mAb) to human HLA-DR, CD14, CD71 and 
CD206. The remaining cells were then used for the analysis of ABC transporter mRNA 
expression using real time PCR (Taqman). 
 
Phenotyping of monocytes showed a high CD14 and HLA-DR expression, whereas the 
differentiation markers CD71 and CD206 were low. During differentiation into MDM CD14 and 
HLA-DR decreased and CD71 and CD 206 increased. Stimulation of MDM with LPS was 
followed by a slight increase of CD14 and HLA-DR. The differentiation marker CD71 and CD 
206 remained unchanged (Table1).  
 
 
monocytes macrophages LPS stimulated 
macrophages 
CD14 521.9 ± 70.7 14.8 ± 3.6 35.7 ± 7.1 
CD71 6.9 ± 1.5 67.6 ± 13.8 69.9 ± 18.2 
CD206 4.4 ± 0.5 15.9 ± 4.5 12.6 ± 3.2 
HLA-DR 226.6 ± 12 120 ± 24.3 150 ± 26 
 
Table1: FACS Analysis of monocytes, macrophages and LPS stimulated macrophages (mean FI ± SEM) 
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Figure 1: MDR1 and BCRP mRNA expression (mean arbitrary units ± SEM) in monocytes, macrophages 
and LPS stimulated macrophages (N=5) 
 
 
  101 
monocytes macrophages LPS stim macrophages
0
500000
1000000
1500000
2000000
2500000
3000000
p < 0.01
p < 0.001
M
RP
1 
m
RN
A 
ex
pr
es
si
o
n
 
(tr
an
sc
rip
t n
u
m
be
r)
 
monocytes macrophages LPS stim macrophages
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
p < 0.001
p < 0.001
M
RP
2 
m
RN
A 
ex
pr
es
si
o
n
 
(tr
an
sc
rip
t n
u
m
be
r)
 
Figure 2A and 2B: MRP1 and MRP2 mRNA expression (mean arbitrary units ± SEM) in monocytes, 
macrophages and LPS stimulated macrophages (N=5) 
 
MDR1 mRNA and BCRP mRNA were not expressed in monocytes. Both transporters showed 
low expression after differentiation into MDM, which decreased insignificantly by activation with 
LPS (Figure1). MRP1 mRNA expression was lowest in monocytes, which increased significantly 
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with differentiation into MDM (p < 0.01) and upon stimulation with LPS (p < 0.001) (Figure 2A). 
In contrast, highest MRP2 mRNA expression was found in monocytes, and was about six fold 
lower after differentiation into MDM (p < 0.001) (Figure 2B).  
A similar expression pattern could be shown for MRP3, MRP4 and MRP5 with the lowest gene 
expression in monocytes and increased gene expression in MDM by 4-fold (p= 0.011), 3-fold (p< 
0.05) and 2.5-fold (p< 0.01), respectively. Gene expression decreased for all three transporters 
in LPS stimulated macrophages (Figure 2C, 2D, 2E). The decrease reached significance only for 
MRP5 (p< 0.01).  
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Figure 2C-E: MRP3-5 mRNA expression (mean arbitrary units ± SEM) in monocytes, macrophages and 
LPS stimulated macrophages (N=5) 
 
4.5 Discussion 
Here, we present an analysis of MDR1, MRP1-5 and BCRP mRNA expression in human 
peripheral blood monocytes and their change after differentiation into monocyte-derived 
macrophages (MDM). Furthermore we investigated the influence of the incubation of MDM with 
lipopolysaccharide (LPS) on the expression level of these transporters. 
In the present study, MDR1 and BCRP mRNA was not expressed in peripheral blood monocytes 
of healthy male donors. After differentiation into MDM for both ABC transporters only low mRNA 
expression could be demonstrated. Comparable results with any expression of P-glycoprotein 
(P-gp) were reported in monocytes and monocyte derived dendritic cells using immunolabeling 
experiments (Laupeze et al., 2001a). Furthermore, neither verapamil nor probenecid, which are 
known inhibitors of P-gp, altered intracellular rhodamine 123 levels in CD14+ monocytes 
(Laupeze et al., 2001b) indicating no functional activity of P-gp in these cells. In contrast, 
intracellular staining of P-gp with monoclonal antibodies was detected in CD14+ monocytes by 
confocal microscopy and in the same study P-gp staining in CD14+ cells was found unaltered in 
blood samples of HIV patients compared to controls (Malorni et al., 1998). MDR1 expression 
was also studied in other cell types of the human peripheral blood. The highest expression was 
found in CD56+ cells, followed by CD8+ > CD4+ > CD19+ cells (Oselin et al., 2003). Puddu et 
al. reported that P-gp expression was upregulated in a dose- and time-dependent manner in 
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MDM by treatment with IFN-γ (Puddu et al., 1999). It was shown that this upregulation was a 
specific response of primary macrophages, as IFN-γ treatment of primary lymphocytes and 
monocytic cell lines did not result in any increase of P-gp expression. Recently, it was suggested 
that P-gp mediated therapy resistance might be a common problem in chronic inflammatory 
processes (Farrell et al., 2000). For example, it was shown that peripheral blood mononuclear 
cells (PBMC) of patients with ulcerative colitis with previous glucocorticoid therapy had 
significant higher levels of MDR1 mRNA compared to patients without history of glucocorticoid 
administration (Hirano et al., 2004). Patients with UC and CD exhibited decreased Pgp 
expression in CD3+ intestinal lymphocytes when compared to healthy controls (Yacyshyn et al., 
1999) and high MDR1 protein expression in CD3+ circulating lymphocytes in IBD patients that 
required surgery several years earlier for failed medical therapy was demonstrated .(Farrell et 
al., 2000) Significantly elevated MDR expression in PBL has been shown also in patients with 
rheumatoid arthritis (RA) that require glucocorticoids (Maillefert et al., 1996).  
BCRP expression was detected mainly in excretory organs, e.g in canalicular membranes of the 
liver, in epithelial cells of the small intestine, colon, kidney and lung as well as in the blood brain 
barrier and the placenta (Scheffer et al., 2000; Maliepaard et al., 2001). It was found to be 
expressed in primitive hematopoietic stem cells (Zhou et al., 2005). However, there are no data 
about BCRP expression in peripheral blood cells. Interestingly, in vitro long term exposure of 
human T-cells to sulfasalazine (SSZ) was leading to an induction of BCRP protein expression 
(van der Heijden et al., 2004). Furthermore, an increase in TNFα release was observed, 
although the anti-inflammatory properties of SSZ, as a disease modifying antirheumatic drug 
(DMARD), have been attributed to diminished production of proinflammatory cytokines such as 
TNFα. Therefore the authors concluded that SSZ can lead to development of resistance by 
induction of BCRP and to a less effective inhibition of nuclear NFκB activation by SSZ in the 
resistant cells. In the same study P-gp was unaffected, while MRP1 expression was 
downregulated.  
In the present study we could demonstrate that the level of MRP1 mRNA and MRP3-5 mRNA is 
significantly lower in monocytes than in MDM. In contrast, the level of MRP2 mRNA expression 
was significantly higher in monocytes than in MDM.  
There are only rare data about expression of MRP1-5 in human peripheral blood cells. It was 
found that normal peripheral blood cells, regardless of cell lineage, expressed a similar basal 
level of MRP mRNA (Abbaszadegan et al., 1994). In another study, MRP1 and MRP2 mRNA 
expression was measured in human peripheral lymphocytes and showed highest expression in 
CD4+ cells, followed by CD8+ > CD19+ > CD56+ cells (Oselin et al., 2003). MRP1 as well as 
  105 
MRP4 and MRP5 mRNA expression was described to be low in MDM cells and in vitro infection 
of MDMs with HIV-1/Ba-L increased the mRNA expression level of MRP1, MRP4 and MRP5 
(Jorajuria et al., 2004b). Incubation of HIV infected MDM with zidovudine, a nucleoside reverse 
transcriptase inhibitors, which is transported by MRP4 and MRP5 (Schuetz et al., 1999; Reid et 
al., 2003), increased MDR1, MRP4 and MRP5 mRNA expression. Also in infected MDM, 
PSC833 (Pgp inhibitor) as well as probenecide (unspecific MRP1 inhibitor) increased the anti-
HIV activity of zidovudine and indinavir, a protease inhibitor, which is transported by MRP1 
(Srinivas et al., 1998), substantially (Jorajuria et al., 2004a). Indinavir (10nM) showed a 14% 
inhibition without and an 81% inhibition in combination with inhibitors.  
Based on these results with zidovudine and indinavir MDM seems to be a suitable model system 
investigating the regulation of expression of multidrug resistance transporters by drugs. These 
drugs should include glucocorticoids (MDR1), methotrexate (MRP1-3), cyclosporine (MDR1), 6-
mercaptopurine (MRP4) and sulfasalazine (BCRP), which all are substrates of MDR transporters 
and are used in treatment of patients with IBD.  
In addition, in the present study, the effect on multidrug resistance tranporter expression after 
LPS incubation of MDM was investigated and a significant increase in MRP1 mRNA expression 
as well as a significant decrease in MRP5 mRNA expression was found. Increased expression 
after LPS administration was also found for MRP2 mRNA and decreased expression was 
observed for BCRP, MDR1, MRP3 and MRP4 mRNA. Lipopolysaccharide (LPS), a component 
of gram negative bacterial cell wall, activates macrophages via binding to the CD14 receptor and 
the signal is mediated by the Toll like Receptor pathway. This initial response to a stimulus is 
followed by production of proinflammatory cytokines leading to a cascade of reactions with 
activation of the NFκB pathway, production of reactive oxygen products and upregulation of 
inducible nitric oxide (NO) synthase (iNOS). To our knowledge, the effects of LPS on MDR 
transporter expression have been studied only in hepatocytes. LPS decreased mRNA levels of 
Mrp2 and increased Mrp1, Mrp3 and Mdr1b mRNA expression in rat hepatocytes, whereas Mrp5 
mRNA was unchanged (Cherrington et al., 2004). Elferink et al studied the effect of endotoxin 
induced cholestasis (with LPS) in rat and human liver. They found that MRP2 mRNA remained 
unchanged in human liver during 24h of incubation with LPS. In contrast MRP protein was 
almost completely removed from the canalicular membrane in the presence of LPS, indicating 
posttranscriptional regulation of protein expression (Elferink et al., 2004). LPS incubation of rat 
liver was leading to downregulation of Mrp2 and to an induction of Mrp3 protein expression in 
periportal hepatocytes and also a strong induction of Mrp5 mRNA was found in the same study 
(Elferink et al., 2004).  
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Our FACS analysis showed that MDM had only low level of CD14 receptors and LPS stimulation 
of MDM was associated with only discrete changes in the expression pattern of MDR 
transporters. Interestingly, Smith et al. demonstrated that intestinal macrophages, which were 
low for CD14 and CD 89 (CD14- and CD89-), have been downregulated for LPS- and IgA 
mediated functions (Smith et al., 2001). So, low level of CD14 receptors with a possible 
downregulation for LPS mediated functions might be an explanation for the only discrete 
changes of expression levels of the investigated drug transporters in our study upon stimulation 
with LPS. 
In conclusion, the mRNA expression level of MDR1, MRP1-5 and BCRP varies in monocytes 
and MDM. While MDR1 and BCRP are not expressed in monocytes and only low in MDM, 
MRP2 is highest expressed in monocytes with significantly lower expression in MDM. MRP1 and 
MRP3-5 show a significant increase when differentiated into MDM. Stimulation of MDM with LPS 
showed a significant increase of MRP1 mRNA and a significant decrease of MRP5 mRNA 
expression. Our results indicate that ABC transporters are adaptively regulated during 
differentiation into MDM and might therefore fulfill different physiological functions. Since many 
drugs that are used in the treatment of acute or chronic inflammatory processes are substrates 
of ABC transporters and macrophages play an important role in the innate immune response, 
MDM could be an interesting cell type studying MDR transporter regulation by anti-inflammatory 
and immunosuppressive drugs. 
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5.1 Abstract 
Objective: Multidrug resistance (MDR) transporters such as MDR1, MRP1-5 and BCRP are 
membrane efflux pumps that extrude drugs such as fluoroquinolones and α-adrenergic 
antagonists, which are used in the treatment of patients with chronic pelvic pain syndrome 
(CPPS), a syndrome caused by inflammatory and non-inflammatory factors. Therapy resistance 
in these patients is a relevant clinical problem. Since biopsies from patients with CPPS could not 
be obtained due to ethical reasons, the aim of the present study was to evaluate the influence of 
inflammation on MDR transporter expression in prostate tissue of patients with benign prostatic 
hyperplasia.  
Methods: BCRP, MDR1 and MRP1-5 mRNA was quantified by real time PCR (Taqman) in 
prostate tissue of 50 patients with benign prostatic hyperplasia. Severity and localization of 
inflammation was assessed on hematoxylin and eosin stained sections. In addition, MDR 
transporter expression in prostate tissue of BPH patients was compared to LNcaP and PC3 
prostate carcinoma cell lines.  
Results: The ranking of transporter gene expression in the prostate tissue of patients with BPH 
was MRP4 = MRP1 >> MRP5 > MRP3 >> MDR1 = BCRP >> MRP2. Neither severity nor 
localization of inflammation in the prostate tissue influenced the expression of these MDR 
transporters. A significant decrease of BCRP mRNA expression (normalized to GAPDH mRNA) 
was observed for BPH patients treated with α-adrenergic antagonists (mean ± SEM) 0.0067 ± 
0.0007 when compared to untreated patients 0.004 ± 0.0005 (p <0.05) before undergoing TUR-
P. Expression of MDR transporters did vary in different prostate carcinoma cell lines (LncaP, 
PC3), when compared to prostate tissue of BPH patients. This indicates that using prostate 
carcinoma cell lines as predictive in vitro models for MDR transporters, variable expression of 
these transporters must be considered. 
Conclusion: Inflammation in the prostate tissue of patients with benign prostatic hyperplasia did 
not influence mRNA expression of BCRP, MDR1 and MRP1-5. 
 
5.2 Introduction 
Multidrug resistance transporter 1 (MDR1; ABCB1), multidrug  resistance associated protein 1-5 
(MRP1-5; ABCC1-5), as well as the breast cancer resistance protein (BCRP; ABCG2) are 
transmembrane efflux pumps that translocate a wide variety of substrates across extra- and 
intracellular membranes using ATP hydrolysis (Horio et al., 1988). They are protecting tissue 
from xenobiotic accumulation and subsequent toxicity by forming a barrier to cellular 
accumulation of toxins as well as to drug absorption (Schinkel, 1997). In consequence they 
  111 
lower the intracellular concentration of these compounds. Multidrug resistance is a phenomenon 
in which a cell exposed to a single drug, becomes cross-resistant to a large number of 
structurally unrelated compounds. Expression of P-glycoprotein (P-gp; gene product of the 
MDR1 gene) in different types of solid tumors and in leukemias has been associated with clinical 
resistance to chemotherapy, indicating that P-gp mediated multidrug resistance is an important 
factor explaining chemotherapy failure in patients with cancer (Plaat et al., 2000; Sonneveld, 
2000). Several studies focused on the expression of multidrug resistance transporters in 
prostate cancer and human prostate cancer cell lines. They found an upregulation of different 
multidrug associated proteins in disseminated, progressive prostate cancer and concluded that 
multidrug resistance transporters may influence response to chemotherapy (van Brussel et al., 
1999; Van Brussel et al., 2001). 
At present, except for P-glycoprotein (gene product of MDR1), which expression has been 
assessed in the healthy prostate (Thiebaut et al., 1987), little is known about the systematic 
expression of other multidrug resistance transporters, such as MRP1-5 and BCRP in prostate 
tissue.  
Besides prostate cancer and benign prostatic hyperplasia (BPH), prostatitis is a challenging 
urological diagnostic entity. Chronic abacterial Prostatitis / Chronic Pelvic Pain Syndrome 
(CPPS, NIH Classification of prostatitis category III) is a common genitourinary diagnosis in the 
18 to 65-year old men (Collins et al., 1998) and presents with discomfort or pain in the pelvic 
region, variable voiding and sexual symptoms. The quality of health of patients with chronic 
prostatitis is impaired (Nickel, 2000). The syndrome is thought to be caused by infectious and 
non-infectious prostatic inflammation as well as noninflammatory disease. The aetiology is not 
known, a microorganism based aetiology with several microbial pathogens, as well as cryptic 
non-cultureable organisms are discussed (Domingue and Hellstrom, 1998). Other possible 
aetiological factors include dysfunctional high-pressure voiding, intraprostatic ductal reflux, 
autoimmune etiology, chemical (urine and its metabolites, i.e. uric acid), neuromuscular and 
others. Antibiotic therapy with the fluoroquinolones ofloxacin and ciprofloxacin or 
trimethoprim/sulfamethoxazole is the recommended treatment of chronic prostatitis, if there is a 
clinical, bacteriological or supporting immunological evidence of prostate infection (Bjerklund 
Johansen et al., 1998). In a telephone survey among primary care physicians (PCP’s) and 
urologists in Canada 1996 fluoroquinolones were thought to result in the successful treatment of 
prostatitis in only 64% of the cases (Nickel et al., 1998). When antibiotics fail other treatments 
are recommended, among others α-blockers as well as anti-inflammatories (NSAIDS) (Nickel, 
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2000). However, these drugs do ameliorate symptoms only in a small part of patients. At 
present, effective management strategies for chronic prostatitis are lacking. 
Taking into account, that there is increasing evidence that several multidrug resistance 
transporter play an important role in acute and chronic inflammatory processes (Wijnholds et al., 
1997; Panwala et al., 1998) and might contribute to the development of therapy resistance in 
certain inflammatory diseases (Maillefert et al., 1996; Farrell et al., 2000), the evaluation of the 
transporter expression in inflamed prostatic tissue might be of therapeutical relevance for 
patients with chronic prostatitis. Because antibiotics (e.g. fluoroquinolones), α-blockers as well 
as anti-inflammatories (NSAIDS) are substrates of multidrug transporters, altered expression of 
P-gp, MRP1-5 or BCRP in inflamed prostatic tissue may influence the intracellular concentration 
of these drugs and the efficacy of these treatments.  
Therefore the aim of this study was to assess the expression of multidrug resistance 
transporters in prostatic tissue of patients with benign prostatic hyperplasia and to evaluate the 
impact of inflammation on the expression level of these transporters. Due to ethical reasons no 
biopsies could be obtained from patients diagnosed with CPPS category III. 
 
5.3 Methods 
Subjects  
In the study 50 consecutive patients with no clinical or laboratory indication for prostate cancer 
that qualified for and underwent transurethral resection of prostate (TUR-P) for benign prostatic 
hyperplasia in the Urology Department of the University Clinic Kantonspital Liestal between April 
2003 and January 2004 were included. Patients, who were treated with known inducers of drug 
metabolising enzymes or MDR transport proteins (such as barbiturates, rifampicin, rifabutin, 
antiepileptics (phenytoin, carbamazepine), HIV protease inhibitors (especially nelfinavir and 
ritonavir), St John’s wort were excluded from the study. The patients were 72 ± 1.2 years (mean 
± SEM) old. All were of Caucasian race and the BMI was 26.7 ± 0.5 kg/m2.  
The study was approved by the local ethic commission (Ethische Kommission beider Basel 
(EKBB)). Patients have signed a written informed consent. 
 
Cell cultures 
The human prostatic carcinoma cell lines LNCaP and PC3 were cultured in standard RPMI 
complete medium, supplemented with 10% (v/v) fetal calf serum, 1% sodium pyruvate, 50µg/ml 
gentamycin and 1% 1M HEPES (pH 7.0). Cells were seeded in 12- well plates (each cell line 
  113 
N=4). Cultures were maintained in a humified 37°C i ncubator with a 5% carbon dioxide in air 
atmosphere.  
 
Real-time polymerase chain reaction analysis of prostate tissue (see Chapter 2) 
Sequence of the primers and probes that were used for TaqMan analysis see in Chapter 2. 
 
Histological assessment 
Histological assessment was done by two trained pathologists. First, frozen sections were fixed, 
sectioned and stained with hematoxylin and eosin. Then, the severity of inflammation was rated 
as follows: 0 = no inflammation, 1 = low, 2 = intermediate, 3 = high grade of inflammation. If 
prostate tissue was found to be inflamed, assessment for localization of inflammation 
acinar/periacinar versus interstitial inflammation was performed. 
 
Data analysis and statistics  
Gene expression was studied in prostate tissue of patients undergoing TUR-P. For the 
comparison of the gene expression level in prostate tissue with different grade of inflammation 
the two-sided Dunnett’s multicomparison t test was used. The level of significance was P <0.05. 
Comparisons were performed using SPSS for windows software (version 12.0, SPSS Inc., 
Chicago, USA). 
 
 
5.4 Results 
 
Expression of multidrug resistance transporters in prostate tissue 
The expression and ranking of all transporters in the prostate tissue normalized to GAPDH is 
shown in Figure 1. MRP4 and MRP1 appeared to be the most abundantly expressed transporter 
in prostate tissue of patients with benign prostatic hyperplasia (BPH) undergoing transurethral 
resection of prostate (TUR-P). MRP3 and MRP5 were found approximately 2 times and MDR1 
and BCRP 6-7 times less expressed than MRP4. Only very low expression was found for MRP2. 
The ranking of transporter gene expression in the prostate tissue of patients with BPH was 
MRP4 = MRP1 >> MRP5 > MRP3 >> MDR1 = BCRP >> MRP2.  
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Figure 1: Expression of MDR1, BCRP and MRP1-5 in the prostate tissue of patients with benign prostatic 
hyperplasia (N=50) normalized to GAPDH expression. Data represent means (± SEM). 
 
Inflammation did not alter the expression of multidrug resistance transporters in prostate 
tissue 
In the histologic assessment, which was done on hematoxylin and eosin stained sections, 13 
patients were found with no inflammation, 10 with low grade, 17 with intermediate and 13 with 
high grade of inflammation in the prostate tissue. Inflammatory cells were found in 6 patients 
predominantly periacinar/acinar, in 24 patients interstitial and in 7 patients both patterns were 
observed. Gene expression of multidrug resistance transporters was not altered neither by 
severity of inflammation nor localization of inflammation (data not shown). 
 
BCRP expression and α-blocker 
BCRP/GAPDH (mean ± SEM) gene expression was significantly decreased in patients with BPH 
treated with α-blocker (0.0067 ± 0.0007; N=12) when compared to α-blocker untreated patients 
(0.004 ± 0.0005; N=38) before TUR-P was performed (p < 0.05) (Figure 2). 
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Figure 2: Comparison of BCRP mRNA expression in patients with benign prostatic hyperplasia treated 
with α-adrenergic antagonist (N = 12) vs. untreated patients (N = 38) before undergoing TUR-P 
normalized to the expression of GAPDH. Data represent means (± SEM).  
 
Expression of multidrug resistance transporters in human prostate carcinoma cell lines 
For evaluation of the multidrug resistance gene expression two prostate carcinoma cell lines 
(LNcaP and PC3) were used and compared to the expression in prostate tissue of BPH patients. 
Almost no BCRP and MDR1 gene expression was found in both prostate cell lines when 
compared to the prostate tissue of BPH patients (Figure 3A and 3B). MRP1 expression in BPH 
patients and in PC3 carcinoma cell line was comparable. MRP1 expression in LNcaP carcinoma 
cell line was 2-3times higher (Figure 3C). As already shown MRP2 expression was very low in 
BPH patients, which is comparable to the PC3 carcinoma cell line. Even lower MRP2 expression 
was found for the LNcaP cell line (Figure 3D). 
MRP3 expression was 20-25times higher in the PC3 cell line compared to prostate tissue of 
BPH patients. No expression of MRP3 was found in the LNcaP cell line (Figure 3E). MRP4 
expression was highest in the LNcaP cell line, followed by PC3 cell line and prostate tissue of 
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BPH patients (Figure 3F). Both cell lines and prostate tissue of BPH patients show an almost 
similar expression level for MRP5 expression (Figure 3G). 
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Figure 3: Expression of MDR1, BCRP and MRP1-5 mRNA in prostate tissue of patients with benign 
prostatic hyperplasia and two prostate carcinoma cell lines (LNcaP, PC3). Data represent mean transcript 
number (± SEM). 
 
 
5.5 Discussion 
Expression of several multidrug resistance (MDR) transporters in patients with BPH was 
evaluated in this study. It could be shown that MRP4 and MRP1 were the two most abundantly 
expressed transporters in the prostate tissue, followed by MRP3 and MRP5. MDR1 and BCRP 
were markedly less expressed, whereas no expression was observed for MRP2. At present 
there is only little information in the literature about the expression of these MDR transporters in 
the human prostate.  
Compared to other tissues such as adrenal gland, kidney, liver, lung as well as the intestine 
MDR1 mRNA expression in prostate tissue was found to be low (Fojo et al., 1987). When 
compared to the liver Uchiumi et al reported minimal expression of MRP3 as well as MRP2 in 
prostate tissue (Uchiumi et al., 1998). In contrast MRP4, which was examined in a range of 
human tissues by hybridization analysis, transcript levels were highest in the prostate (Lee et al., 
1998). MRP4 was localized on the basolateral membrane of tubuloacinar cells and it was 
suggested that one function of MRP4 might be the efflux of xenobiotics and toxins out of 
prostatic epithelial cells (Lee et al., 1998).  
MDR1 was detected in both benign and malignant prostate cells (Kawai et al., 2000). In non-
malignant prostate tissue P-glycoprotein (Pgp; the gene product of MDR1) was detected on the 
apical membrane of the epithelial cells with higher staining intensity towards the inner zone, 
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whereas in malignant specimens Pgp showed lower staining intensities and was found to be 
expressed more heterogeneously in the cancer tissue (Kawai et al., 2000). Almost all clinical 
based studies investigating the role of MDR transporters in human prostate were focusing on 
prostate cancer. Although MDR1 was not expressed in diverse prostate carcinoma cell lines 
(van Brussel et al., 1999) a direct correlate was found between tumor grade, stage and prostate 
specific antigen levels in a retrospective analysis of paraffin-embedded tissue of patients with 
prostate cancers and controls with BPH (Bhangal et al., 2000).  
MRP1 is consistently expressed in prostate cancer cell lines (van Brussel et al., 1999) and was 
found to be expressed even in early stages of prostate cancer (Sullivan et al., 1998) with an 
increase in late disease stages (Van Brussel et al., 2001). Drug resistance phenotype due to 
incubation with doxorubicin was reported for various prostate carcinoma cell lines (David-
Beabes et al., 2000). 
Chronic abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CPPS, NIH Classification of 
prostatitis category III) is thought to be caused by infectious and non-infectious prostatic 
inflammation as well as noninflammatory disease. Patients with CPPS often do not respond to 
first line treatment with antibiotics and subsequently also fail to benefit from second line 
treatments such as α-blockers as well as anti-inflammatories (NSAIDs). Fluoroquinolones are 
the recommended antibiotics in the treatment of chronic prostatitis (Bjerklund Johansen et al., 
1998). Interestingly, several fluoroquinolones are substrates of different MDR transporters as 
shown in transport assays performed in different tissue types and cell lines (Tamai et al., 2000; 
Terashi et al., 2000; Lowes and Simmons, 2002; Michot et al., 2004; Sasabe et al., 2004). α-
Adrenergic antagonists such as Prazosin and Doxazosin are substrates of BCRP (Ozvegy et al., 
2001) and of MDR1 (Takara et al., 2002), respectively. Aspirin was shown to enhance Pgp 
expression in a human lymphoma cell line. MRP4 acts as a prostaglandin transporter and 
nonsteroidal anti-inflammatory drugs were shown to inhibit this transport (Reid et al., 2003). As 
several MDR transporters play an important role in acute and chronic inflammatory processes 
(Wijnholds et al., 1997; Panwala et al., 1998) and might contribute to the development of therapy 
resistance in certain inflammatory diseases (Maillefert et al., 1996; Farrell et al., 2000), the aim 
of the present study was to evaluate the influence of inflammation in prostate tissue of BPH 
patients on MDR transporter expression. Due to ethical reasons, tissue of patients with CPPS 
could not be obtained. 
Here, the grade of inflammation and localization of inflammation (acinar/periacinar versus 
interstitial) was assessed on hematoxylin and eosin stained sections on prostate tissue of 
patients with BPH. Neither severity nor localization of inflammation changed the expression of 
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the investigated MDR transporters. The influence of inflammation on MDR transporter 
expression in prostate tissue of patients with BPH or of patients with chronic prostatitis has not 
been reported in the literature before. However, in a rat prostatitis model poor success rate of 
treatment with norfloxacin was not due to altered pharmacokinetics in the inflamed prostate 
(Nickel et al., 1995). This could implicate that transporters did not influence the transport of 
norfloxacin in this model. 
Patients treated with an α-adrenergic antagonist before undergoing resection of prostate showed 
a decreased BCRP expression when compared to the untreated group. Of these 12 patients, 8 
were taking tamsulosin, 2 terazosin and 2 alfuzosin. These patients were taking the medication 
until TUR-P was performed. Tamsulosin is a potent α-blocker which is metabolised by CYP3A4 
and CYP2D6 (Kamimura et al., 1998). If tamsulosin is transported by an MDR transporter is 
currently not known. As the influence of α-adrenergic antagonists on MDR expression was not a 
primary question of this study the result here is not conclusive and needs to be confirmed. 
 
In addition, the expression of MDR transporters in prostate tissue of BPH patients as well as in 
two prostate carcinoma cell lines (LNcaP and PC3) was evaluated. It could be shown, that 
BCRP and MDR1 mRNA expression was very low in both prostate carcinoma cell lines when 
compared to the prostate tissue of BPH patients. MRP1 expression in BPH patients and in PC3 
carcinoma cell line was comparable, but MRP1 expression in the LNcaP carcinoma cell line was 
2-3times higher. MRP2 expression was very low in BPH patients with a comparable expression 
level in PC3 carcinoma cell line. MRP3 expression was 20-25times higher in the PC3 cell line 
when compared to prostate tissue of BPH patients. No expression of MRP3 was found in the 
LNcaP cell line. MRP4 expression was highest in the LNcaP cell line, followed by PC3 cell line 
and prostate tissue of BPH patients. Both prostate carcinoma cell lines and prostate tissue of 
BPH patients show an almost similar expression level concerning MRP5 expression. In general, 
expression of MDR transporters showed variable expression levels in the prostate carcinoma 
cell lines and in prostate tissue of BPH patients. In consequence, when prostate carcinoma cell 
lines are used as predictive in-vitro models for MDR variable expression of these transporters 
must be considered.  
 
In conclusion, the ranking of transporter gene expression in the prostate tissue of patients with 
BPH was MRP4 = MRP1 >> MRP5 > MRP3 >> MDR1 = BCRP >> MRP2. Neither severity nor 
localization of inflammation in the prostate tissue influenced the expression of these MDR 
transporters. A significant decrease of BCRP mRNA expression was observed for BPH patients 
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treated with α-adrenergic antagonists before undergoing TUR-P when compared to untreated 
patients. However, this result needs to be confirmed on the posttranscriptional level. Expression 
of MDR transporters did vary in different prostate carcinoma cell lines (LncaP, PC3), when 
compared to prostate tissue of BPH patients and indicates that choice of carcinoma cell lines for 
in vitro studies with MDR transporters has to be done carefully. 
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Conclusion and Outlook 
 
The aim of this thesis was to investigate the role of transmembrane transporters in healthy 
intestine and gastrointestinal diseases. In healthy subjects, systematic site-specific analysis of 
various transmembrane transporters along the intestinal tract was presented here (Chapter 3.1, 
3.2, 3.4). All investigated transporters showed alterations in their mRNA expression levels from 
the duodenum to the sigmoid colon. As many of the investigated tranporters were efflux 
transporters such as MDR1, BCRP, MRP1-5 which are localized in the intestinal wall and restrict 
intestinal drug transport, this knowledge might be important to develop drug targeting strategies 
for orally administered drugs.  
During obstructive cholestasis, expression and regulation of ASBT, which is a critical 
determinant of the reuptake of bile acids from the intestine and of BCRP, which mediates among 
others energy dependent efflux of bile acids, were investigated. Both transporters were 
downregulated during obstructive cholestasis. We concluded that for ASBT adaptive gene 
regulation may represent a mechanism preventing the accumulation of hepatotoxic bile acids 
during cholestasis. Reduced intestinal BCRP expression during cholestasis might influence the 
accumulation of bile acids, food-derived carcinogens and the pharmacokinetics of various drugs 
that are transported by BCRP. However, the molecular mechanisms explaining this observed 
adaptive regulation, which might be mediated by bile acids, drugs, inflammatory cytokines or 
other factors, are not known. In the literature several nuclear receptors have been described to 
be involved in the regulation of ASBT (Chapter 1.3). PPARα, which is one of these nuclear 
receptors, was not significantly different between cholestatic patients and controls. In 
conclusion, additional studies are needed to investigate the molecular factors which are involved 
in the regulation of gastrointestinal transporters involved in bile acid transport during obstructive 
cholestasis.  
 
To understand the molecular mechanisms for insufficient or failed therapy in the treatment of 
patients with Inflammatory Bowel Disease (IBD) is another key project of our laboratory. 
Intestinal macrophages play a central role in the orchestration of innate immune response 
reactions in the gut and anti-inflammatory and/or immunosuppressive drugs such as 
glucocorticoids (MDR1), methotrexate (MRP1-3), cyclosporine (MDR1), 6-mercaptopurine 
(MRP4) and sulfasalazine (BCRP), which all are used in the treatment of IBD patients, are 
substrates of MDR transporters. 
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Therefore, a method for isolation of CD14+ peripheral blood cells (monocytes), their ex vivo 
cultivation and differentiation into macrophages was established. First, the influence of the 
differentiation process of monocytes into monocyte derived macrophages (MDM) and the 
stimulation of bacterial products (LPS) of MDM on MDR transporter expression was 
investigated, as demonstrated. At present, the effect of budesonide, methotrexate, 6-
mercaptopurine and sulfasalazine on the transporter expression in ex vivo cultivated human 
MDM is evaluated.  
In a next step, we will isolate CD14+ monocytes from peripheral blood mononuclear cells from 
healthy controls, UC patients, and CD patients, differentiate them into MDM, and characterize 
them regarding MDR transporter expression patterns.  
 
In addition, it is planned to extract lamina propria mononuclear cells and intraepithelial 
lymphocytes from intestinal mucosa. This method will be established using larger samples from 
porcine intestine, with the aim to try to down-scale the method to smaller tissue sample sizes (as 
for human biopsies). Subsequently, the method will be transferred to biopsies of human 
intestinal tissues. Alternatively, the use of human surgically resected intestinal tissue is 
foreseen. Primary cell cultures of these cellular subtypes will be investigated by means of 
quantitative real-time PCR analysis, Western blot, and fluorescence activated cell sorting 
(FACS) to study the expression pattern of MDR transporters.  
At present, effects of IBD drugs, e.g. budesonide on MDR mRNA and protein expression in 
different intestinal epithelial cell lines (LS180, Caco-2 and HT29) are systematically evaluated. In 
our in vitro studies we are focusing on nuclear receptors such as the glucocorticoid receptor 
(GR) and pregnane X receptor (PXR) with the goal to gain more insight in the molecular 
mechanisms underlying glucocorticoid resistance or dependence often seen in IBD patients.  
The human ASBT gene has been shown to be transactivated by the GR and its ligands 
dexamethasone and budesonide. Induction of ASBT expression in the intestine of Crohn 
patients may improve the chologenic component of diarrhea. In a subproject we plan to evaluate 
the expression of ASBT in Crohn patients which are not responding to treatment with steroids.  
 
Another important task of our group and of my present work was to initiate a prospective clinical 
study in IBD patients, which should investigate MDR transporter gene expression in intestinal 
biopsies (intestinal epithelial cells, intestinal macrophages) and blood samples (lymphocytes) in 
newly diagnosed IBD patients compared to treatment refractory IBD patients, patients in 
remission and disease free controls. The aim of the study is to investigate the expression of 
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MDR transporter in intestinal tissue biopsies and blood samples to demonstrate, if the 
expression levels of MDR transporters vary due to: 
- inter-individual differences 
- inflammatory processes  
- pharmacological treatment  
 
For analysis of MDR transporter expression TaqMan analysis, Western blot and immunostaining 
will be applied. 
For the analysis 5 patient groups of 60 patients each are needed: A) new, untreated patients 
(aged 18-60 years) with Crohn’s disease, B) new untreated patients with ulcerative colitis , C) 
therapy refractory patients with IBD, D) IBD patients in remission and E)  patients with irritable 
bowel syndrome (control group, see below) undergoing colonoscopy. In patients with 
macroscopical signs of inflammation, biopsies from the inflammed and when possible also from 
the non-inflammed part are taken. Up to now, a total number of 130 patients have been included 
into the study and biopsies have been collected. Unfortunately, no preliminary analysis could be 
presented in this thesis. 
In collaboration with external gastroenterologists blood samples of IBD patients will be collected 
for the analysis of “Single nucleotide polymorphisms (SNP)” of different MDR transporter genes. 
It will be evaluated, if the SNP´s can be used as predictors for susceptibility and/or treatment 
responsiveness. Allelic discrimination assays for other SNPs of ABC-transporters such as a 5’-
nuclease assay for the MDR1G2677T and the MDR1G2677A polymorphism have already been 
established by Heike Gutmann in our group, whereas allelic discrimination assays for other 
multidrug transporters such as BCRPG34A, BCRPC421A, BCRPA616C, and BCRPA1768T are 
in development currently.  
 
The “prostate study” was performed to evaluate the influence of inflammation on expression of 
MDR tranporters in patients with BPH. Neither severity nor localization of inflammation altered 
the expression of the investigated MDR transporters. This project was designed as an isolated 
project and will not be investigated further. 
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